text
"['\n6. 주요계약 및 연구개발활동\n(1)\xa0\n경영상의\n\xa0\n주요\n\xa0\n계약\n\xa0\n등\n(가)\xa0라이선스\xa0아웃\xa0계약해당\xa0사항\xa0없음 (나)\xa0라이선스\xa0인\xa0계약공시\xa0서류\xa0작성기준일\xa0현재\xa0당사가\xa0체결\xa0중인\xa0라이선스\xa0인\xa0계약의\xa0현황은\xa0다음과\xa0같습니다.  <라이선스인\xa0계약\xa0총괄표>\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0(\r\n단위:백만원)\n품목\n계약상대방\n대상지역\n계약체결일\n계약종료일\n총\n\xa0\n계약금액\n수취금액\n진행단계\n쓴맛\xa0수용체\xa0신호전달물질\xa0및\xa0기술\nThe Trustees of the University \xa0of Pennsylvania\n전\xa0세계\n2018년\xa06월\xa020일\n1)\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\n2)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa010년중\xa0늦은\xa0날\n라이선스\xa0발행\xa0수수료\xa01만불\xa0외\xa0년간라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\n-\n임상2상\n약물\xa0전달법\nRUTGERS, THE STATE UNIVERSITY OF NEW JERSEY\n전\xa0세계\n2018년\xa010월\xa022일\n1)\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\n2)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa010년\n중\xa0늦은\xa0날\n라이선스\xa0발행\xa0수수료\xa05천불\xa0외\xa0년간라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\n-\n비임상\n니파(Nipah)\xa0및\xa0포와산\xa0(Powassan)\xa0바이러스를\xa0예방하는\xa0핵산\xa0기반\xa0백신\xa0후보물질의\xa0기술\xa0\nTHE WISTAR INSTITUTEOF ANATOMY AND BIOLOGY\n전\xa0세계\n2021년\xa012월\xa07일\n1)\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\n2)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa012년\xa0후\n첫\xa0번째\xa0라이선스\xa0발행\xa0수수료\xa02만5천불과\xa0두\xa0번째\xa0라이선스\xa0발행\xa0수수료\xa05만불\xa0외\xa0라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\xa0\n-\n비임상\n 1)\xa0품\xa0목\xa0:\xa0쓴맛\xa0수용체\xa0신호전달\xa0물질\xa0및\xa0기술\n1.\xa0계약\xa0상대방\n미국, The Trustees of the University of Pennsylvania\n2.\xa0계약\xa0내용\n계약상대방이\xa0보유한\xa0호흡기\xa0감염의\xa0치료제\xa0개발을\xa0위한\xa0쓴맛\xa0수용체\xa0신호전달\xa0물질\xa0및\xa0쓴맛\xa0수용체\xa0진단법\xa0개발\xa0기술에\xa0대해\xa0당사가\xa0독점적인\xa0라이선스를\xa0갖게\xa0됨\n3.\xa0대상\xa0지역\n전\xa0세계\n4.\xa0계약\xa0기간\n계약\xa0체결일\xa0: 2018년\xa06월\xa020일\xa0계약\xa0종료일\xa0: 1)\xa0본건\xa0관련\xa0계약상대방이\xa0보유한\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\xa02)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa010년\xa0중\xa0늦은\xa0날\n5.\xa0총\xa0계약\xa0금액\n라이선스\xa0발행\xa0수수료\xa0약\xa012백만원(US$10,000)\xa0외\xa0년간\xa0라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\n6.\xa0계약\xa0조건\n계약금\xa0: \xa0약\xa012백만원(US$10,000), \xa0지급\xa0조건:\xa0계약\xa0체결\xa0시\n매년\xa0라이선스\xa0유지\xa0수수료\xa0약\xa012백만원(US$10,000)\xa0지급\n마일스톤\xa0: \xa0 \xa0 \xa0\xa0\n마일스톤\n로열티\xa0:\xa0순매출액의\xa0 2%, \xa0지급\xa0조건\xa0:\xa0매출\xa0발생\xa0시\xa0분기별\xa0지급,\xa0최소\xa0연례\xa0로열티\xa050만불\n서브-라이선스\xa0수입에\xa0대해서는\xa025%\xa0지급,\xa0임상3상\xa0첫\xa0번째\xa0피험자\xa0투여\xa0후에는\xa015%\xa0지급하기로\xa0함\n기존\xa0특허\xa0비용\xa0$39,691.15를\xa0지급하고, $25,000\xa0한도\xa0내에서\xa0특허\xa0관련\xa0비용을\xa0보전해\xa0주기로\xa0함\n7.\xa0회계\xa0처리\xa0방법\n계약금,\xa0라이선스\xa0유지\xa0수수료\xa0-\xa0일시에\xa0비용\xa0인식\n마일스톤:\xa0임상2상까지\xa0전액\xa0비용\xa0처리,\xa0임상3상\xa0승인\xa0이후의\xa0마일스톤은\xa0무형자산으로\xa0계상\n8.\xa0대상\xa0기술\n호흡기\xa0감염의\xa0치료제\xa0개발을\xa0위한\xa0쓴맛\xa0수용체\xa0신호전달\xa0물질\xa0및\xa0쓴맛\xa0수용체\xa0진단법\xa0\n9.\xa0개발\xa0진행\xa0경과\n<거래\xa0상대방>\n코\xa0분무기(Nasal spray)를\xa0이용한\xa0비염,\xa0축농증\xa0치료제의\xa0안전성과\xa0유효성\xa0확인을\xa0위한\xa01/2상\xa0임상\xa0연구\xa0종료\xa0(지역\xa0:\xa0미국,\xa0임상단계\xa0: 1/2상,\xa0임상시작일\xa0: 2015년\xa010월,\xa0임상\xa0완료일\xa0: 2017년\xa05월) <회사>비염,\xa0축농증\xa0치료를\xa0위한\xa02상\xa0임상\xa0연구를\xa0위해,\xa0미국\xa0FDA에\xa0임상\xa0승인(2020년\xa04월13일)\xa0\n코로나19\xa0감염방지를\xa0위한\xa0코\xa0스프레이\xa0치료제의\xa0미국\xa0FDA 2상\xa0임상\xa0승인(2020년\xa04월\xa029일)\n미국\n\xa0\n펜실베니아\n\xa0\n임상시험센터에\n\xa0\n첫\n\xa0\n대상자의\n\xa0\n최초\n\xa0\n투여\n\xa0\n진행\n\xa0(2020\n년\n9\n월\n)\n미국\n\xa0\n특허청으로부터\n\xa0\n코\n\xa0\n스프레이\n\xa0\n치료제\n\xa0\n및\n\xa0\n축농증\n\xa0\n치료제의\n\xa0\n원천\n\xa0\n기술에\n\xa0\n대한\n\xa0\n특허\n\xa0\n등록\n\xa0(2021\n년\n1\n월\n)\n미국\n\xa0\n내\n\xa02\n차\n\xa0\n임상시험\n\xa0\n실시기관\n\xa0\n추가\n\xa0\n및\n\xa0\n임상시험대상자를\n\xa0\n일반인으로\n\xa0\n확대\n\xa0\n진행하고자\n\xa0\n미국\n\xa0IRB\xa0\n승인\n\xa0\n득함\n\xa0(2021\n년\n4\n월\n)\n임상시험대상자\n\xa0225\n명\n\xa0\n등록\n\xa0\n계획\n\xa0\n중\n184\n명\n\xa0\n등록\n\xa0\n완료\n(2022\n년\n12\n월\n)\n코로나\n19\n에\n\xa0\n감염된\n\xa0\n대상자\n\xa0\n모집의\n\xa0\n고충으로\n\xa0\n대상자\n\xa0\n모집\n\xa0\n조기\n\xa0\n종료\n(2022\n년\n12\n월\n)\n\xa0\n10.\xa0기타\xa0사항\n없음\n 2)\xa0품\xa0목\xa0:\xa0약물\xa0전달법\n1.\xa0계약\xa0상대방\n미국, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY\n2.\xa0계약\xa0내용\n계약상대방의\xa0약물\xa0전달법에\xa0대해\xa0당사가\xa0독점적인\xa0라이선스를\xa0갖게\xa0됨\n3.\xa0대상\xa0지역\n전\xa0세계\n4.\xa0계약\xa0기간\n계약\xa0체결일\xa0: 2018년\xa010월\xa022일\xa0계약\xa0종료일\xa0: 1)\xa0본건\xa0관련\xa0계약상대방이\xa0보유한\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\xa02)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa010년\xa0중\xa0늦은\xa0날\n5.\xa0총\xa0계약\xa0금액\n라이선스\xa0발행\xa0수수료\xa0약\xa06백만원(US$5,000)\xa0외\xa0년간\xa0라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\n6.\xa0계약\xa0조건\n계약금\xa0: \xa0약\xa06백만원(US$5,000), \xa0지급\xa0조건:\xa0계약\xa0체결\xa0후\xa030일\xa0이내\n라이선스\xa0유지\xa0수수료: \xa01-2년\xa0차\xa0매년\xa02천불, 3년차\xa04천불, 4년차\xa0이후\xa0매년\xa05천불->상업적\xa0판매\xa0개시\xa0후\xa0지급하지\xa0않음\n마일스톤\xa0: \xa0\xa0\n\xa0\n마일스톤 지급일정표\n로열티\xa0:\xa0순매출액의\xa0 2.5%, \xa0지급\xa0조건\xa0:\xa0매출\xa0발생\xa0시\xa0분기별\xa0지급,\xa0단,\xa0아래\xa0표와\xa0같이\xa0최소\xa0연례\xa0로열티를\xa0지급하기로\xa0함\n연례 로열티 지급표\n서브-라이선스\xa0수입에\xa0대해서는\xa0계약\xa0후\xa04년\xa0이내는\xa010%, 4년\xa0후부터는\xa05%를\xa0지급하기로\xa0함.\xa0단,\xa0상업적\xa0판매\xa0개시\xa0후\xa0서브-라이선스에\xa0대해서는\xa0수수료를\xa0지급하지\xa0않음\n7.\xa0회계\xa0처리\xa0방법\n계약금,\xa0라이선스\xa0유지\xa0수수료\xa0-\xa0일시에\xa0비용\xa0인식\n마일스톤:\xa0임상\xa02상까지\xa0전액\xa0비용\xa0처리,\xa0임상3상\xa0승인\xa0이후의\xa0마일스톤은\xa0무형자산으로\xa0계상\xa0\n8.\xa0대상\xa0기술\n약물\xa0전달법\n9.\xa0개발\xa0진행\xa0경과\n<거래\xa0상대방>\n\xa0해당\xa0약물\xa0전달법\xa0이용\xa0기능적인\xa0견본품\xa0제작\xa0및\xa0실험실\xa0내\xa0효능평가를\xa0동물에서\xa0수행\xa0완료\xa0\n<회사>실험실\xa0내\xa0효능평가에\xa0필요한\xa0DNA\xa0후보물질\xa0연구용\xa0시료\xa0생산\xa0완료.\xa0동물\xa0효능평가\xa0완료\xa0후\xa0확보된\xa0시료\xa0이용\xa0면역반응\xa0평가\xa0중\n10.\xa0기타\xa0사항\n없음\n\xa0\n3)\xa0품\xa0목\xa0:\xa0니파(Nipah)\xa0및\xa0포와산\xa0(Powassan)\xa0바이러스를\xa0예방하는\xa0핵산\xa0기반 \xa0\xa0백신\xa0후보물질의\xa0기술\n1.\xa0계약\xa0상대방\n미국, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY\n2.\xa0계약\xa0내용\n계약\xa0상대방이\xa0보유한\xa0니파\xa0(Nipah)\xa0및\xa0포와산\xa0(Powassan)\xa0바이러스를\xa0예방하는\xa0DNA\xa0백신\xa0후보물질의\xa0기술에\xa0대해\xa0당사가\xa0독점적인\xa0라이선스를\xa0갖게\xa0됨\xa0\n3.\xa0대상\xa0지역\n전\xa0세계\n4.\xa0계약\xa0기간\n계약\xa0체결일\xa0: 2021년\xa012월\xa07일\xa0계약\xa0종료일\xa0: 1)\xa0본건\xa0관련\xa0계약상대방이\xa0보유한\xa0마지막\xa0특허의\xa0만료\xa0또는\xa0포기일\xa02)\xa0첫\xa0번째\xa0상업적\xa0판매\xa0후\xa012년\xa0후\n5.\xa0총\xa0계약\xa0금액\n총\xa0라이선스\xa0발행\xa0수수료\xa0약\xa093백만원(US$75,000)\xa0외\xa0년간\xa0라이선스\xa0유지\xa0수수료,\xa0마일스톤,\xa0로열티\xa0등\xa0별도\n6.\xa0계약\xa0조건\n계약금\xa0: \xa0약93백만원(US$75,000), \xa0지급\xa0조건:\xa0계약\xa0체결\xa0시와\xa01년\xa0뒤\xa0또는\xa0제품\xa0개발\xa0자금\xa0조달시\n라이선스\xa0유지\xa0수수료\xa0 : \xa02023년\xa01월\xa01일까지\xa0약12백만원(US$10,000)\xa0지급, 2024~2028\xa0년간\xa0약18백만원\xa0(US$15,000)\xa0지급,2029~계약종료일\xa0년간\xa0약31백만원(US$25,000)\xa0지급\xa0\xa0\n마일스톤\xa0: \xa0 \xa0 \xa0 \n마일스톤\n로열티\xa0:\xa0총\xa0순매출액\xa0약1,200억원(US$100,000,000)\xa0미만\xa0시\xa0 4%, \xa0지급\xa0조건\xa0:\xa0매출\xa0발생\xa0시\xa0분기별\xa0마지막\xa0날로부터\xa030일\xa0이내\xa0지급\n총\xa0순매출액\xa0약1,200억원(US$100,000,000)\xa0이상\xa0시\xa05%,\xa0지급\xa0조건:\xa0매출\xa0발생\xa0시\xa0분기별\xa0마지막\xa0날로부터\xa030일\xa0이내\xa0지급\n연례로열티 지급표\n서브-라이선스\xa0수입에\xa0대해서는\xa0첫\xa0IND\xa0제출일까지\xa020%\xa0지급,\xa0첫\xa0IND\xa0제출일\xa0이후\xa0임상\xa02상\xa0첫\xa0번째\xa0피험자\xa0투여일까지는\xa015%\xa0지급,\xa0임상\xa02상\xa0첫\xa0번째\xa0피험자\xa0투약일\xa0이후\xa0본\xa0계약서\xa0종료일까지는\xa010%\xa0지급하기로\xa0함\xa0\n7.\xa0회계\xa0처리방법\n계약금,\xa0라이선스\xa0유지\xa0수수료\xa0-\xa0일시에\xa0비용\xa0인식\n마일스톤:\xa0임상2상까지\xa0전액\xa0비용\xa0처리,\xa0임상3상\xa0승인\xa0이후의\xa0마일스톤은\xa0무형자산으로\xa0계상\xa0\n8.\xa0대상\xa0기술\n니파\xa0(Nipah)\xa0및\xa0포와산\xa0(Powassan)\xa0바이러스를\xa0예방하는\xa0DNA\xa0백신\xa0후보물질의\xa0기술\n9.\xa0개발\xa0진행\xa0경과\n<거래\xa0상대방>\n포와산\xa0(Powassan)\xa0바이러스를\xa0예방하는\xa0DNA\xa0백신의\xa0효능평가를\xa0동물에서\xa0수행\xa0완료\xa0및\xa0해당\xa0연구\xa0결과를\xa0퍼블릭\xa0라이브러리\xa0오브\xa0사이언스\xa0(PLOS Neglected Infectious Diseases)에\xa0게재함\xa0(2020년\xa010월\xa029일)\n니파\xa0(Nipah)\xa0바이러스를\xa0예방하는\xa0DNA\xa0백신이\xa0쥐\xa0동물실험에서\xa0바이러스\xa0항체\xa0생성을\xa0확인함(2019년\xa07월\xa016일\xa0The Wistar Institute blog)\n\xa0\n<회사> \xa0전임상\xa0연구\xa0준비\xa0중\xa0\n10.\xa0기타\xa0사항\n없음\n\xa0\n(2)\xa0\n연구개발\n\xa0\n활동\n1)\xa0\n연구개발\n\xa0\n활동의\n\xa0\n개요\n당사는\xa0핵산\xa0기반\xa0바이오\xa0신약과\xa0항염증\xa0치료\xa0신약을\xa0연구개발하고\xa0있습니다.\xa0핵산\xa0\xa0기반\xa0바이오\xa0신약은\xa0DNA\xa0기반\xa0의약품과\xa0mRNA\xa0기반\xa0의약품으로\xa0나눌\xa0수\xa0있으며, \xa0치료\xa0목적에\xa0따라\xa0핵산\xa0기반\xa0백신,\xa0핵산\xa0기반\xa0유전자\xa0의약품으로\xa0구성되어\xa0있습니다.\xa0항염증\xa0치료\xa0신약은\xa0천연물\xa0유래\xa0성분\xa0의약품과\xa0화학합성\xa0의약품으로\xa0나눌\xa0수\xa0있습니다.\nDNA\xa0기반\xa0의약품\xa0중\xa0DNA\xa0백신은\xa0다수의\xa0제품이\xa0국내외\xa0임상\xa0연구를\xa0수행\xa0중에\xa0있으며, DNA\xa0기반\xa0단백질의약품\xa0및\xa0단클론항체\xa0의약품은\xa0타당성\xa0검증연구를\xa0통해\xa0전임상\xa0개발\xa0후보물질을\xa0도출하고\xa0있으며, mRNA\xa0기반\xa0의약품은\xa0연구개발\xa0기반\xa0구축\xa0및\xa0전임상\xa0개발\xa0후보물질의\xa0도출을\xa0준비하고\xa0있습니다.\n항염증\xa0치료\xa0신약인\xa0천연물\xa0유래\xa0성분\xa0의약품과\xa0저분자량\xa0화학합성\xa0의약품은\xa0글로벌\xa02상\xa0임상시험\xa0단계에\xa0있습니다. \xa0\n\xa0\n2)\xa0\n연구개발\n\xa0\n담당조직\n①\xa0\n연구개발\n\xa0\n조직\n\xa0\n개요\n당사의\xa0연구개발\xa0조직은\xa0기업부설\xa0R&D\xa0연구소와\xa0신약개발본부(서울시\xa0영등포구\xa0소재),\xa0글로벌\xa0임상개발본부(미국\xa0소재)로\xa0구성되었으며,\xa0기업부설\xa0R&D\xa0연구소는\xa0산하연구개발팀과\xa0전략기획팀을\xa0두고\xa0있습니다.\xa0당사\xa0연구개발조직\xa0현황은\xa0다음과\xa0같습니다.\n <연구개발\xa0조직\xa0구성>\n구\n\xa0 \xa0\n분\n팀\n주요업무\n기업부설\xa0\nR&D\xa0연구소\n핵산기반\xa0백신\xa0및\xa0신약연구개발팀전략기획팀\n-\xa0핵산\xa0기반\xa0바이오\xa0의약품의\xa0타겟\xa0발굴\xa0및\xa0전임상\xa0연구\n-\xa0오픈\xa0이노베이션을\xa0통한\xa0바이오\xa0의약품\xa0혁신\xa0기술\xa0개발\n-\xa0신약\xa0개발\xa0파이프라인\xa0개발\xa0및\xa0국내외\xa0현황과\xa0특허\xa0조사\n신약개발본부\xa0\n임상개발팀,\xa0\n임상면역반응\xa0분석팀\n-\xa0핵산\xa0기반\xa0백신\xa0및\xa0항염증\xa0치료\xa0의약품의\xa0국내\xa0IND\xa0승인\xa0및\xa0임상시험\xa0일정\xa0및\xa0진도\xa0관리\n-\xa0임상\xa0효능\xa0평가를\xa0위한\xa0임상검체\xa0면역반응\xa0분석\n- IND package의\xa0Non-GLP\xa0비임상시험\xa0수행\xa0및\xa0분석\xa0\n글로벌임상개발\xa0본부\n임상면역학\xa0실험실\n-\xa0핵산\xa0기반\xa0바이오\xa0신약과\xa0항염증\xa0치료\xa0신약의\xa0국내외\xa0임상\xa0면역원성\xa0평가시험\xa0개발,\xa0수행\xa0및\xa0관리\xa0\nClinical Project Management\xa0팀\n-\xa0핵산\xa0기반\xa0바이오\xa0신약과\xa0항염증\xa0치료\xa0신약의\xa0글로벌\xa0임상시험\xa0관리\n <조직도>\n\xa0\n연구소 조직도\n②\xa0\n연구개발\n\xa0\n인력\n\xa0\n현황\n공시\xa0서류\xa0작성기준일\xa0현재\xa0당사는\xa0박사급\xa015명,\xa0석사급\xa09명\xa0등,\xa0총\xa025명의\xa0연구\xa0인력을\xa0보유하고\xa0있으며,\xa0그\xa0현황은\xa0다음과\xa0같습니다.<\n연구개발\n\xa0\n인력\n\xa0\n현황\n>\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위\xa0:명)\n구분\n인원\n박사\n석사\n기타\n합계\n기업부설 \xa0R&D\xa0연구소\n신약연구개발팀\n전략기획팀\n7\n3\n\xa0-\n10\n신약개발본부\n임상면역반응\xa0분석팀\n임상개발팀\n2\n4\n-\n6\n글로벌임상\n개발본부\n임상면역학\xa0실험실\n3\n2\n1\n6\nClinical Project Management팀\n3\n-\n-\n3\n계\n15\n9\n1\n25\n③\xa0\n핵심\n\xa0\n연구인력\n당사의\xa0핵심\xa0연구\xa0인력은\xa0최고의학책임자인\xa0죠엘\xa0메슬로(Joel N. Maslow),\xa0최고과학개발책임자인\xa0카\xa0무투마니(Kar Muthumani),\xa0기업부설\xa0R&D\xa0연구소장\xa0이사\xa0김원일,\xa0신약개발본부\xa0이사\xa0권이주,\xa0임상\xa0중개연구\xa0책임자\xa0크리스틴\xa0로버츠(Christine C. Roberts)\xa0이며,\xa0그\xa0현황은\xa0다음과\xa0같습니다.\n\xa0\n<\n핵심\n\xa0\n연구\n\xa0\n인력\n\xa0\n현황\n>\n직위\n성명\n담당업무\n주요경력\n주요\n\xa0\n연구실적\n최고의학책임자\n죠엘\xa0메슬로\n(Joel N. Maslow)\n임상개발\xa0총괄\n* Univ. of Virginia, Ph.D. Physics (’83)\n* Jefferson Medical College, M.D. (’84)\n* Drexel University,\xa0\n\xa0M.B.A. (’08)\n* Morristown Medical Center, Chief, Division of Infectious Diseases (‘12~’16)\n* St. Georges School of Medicine, Professor of Medicine (‘12~’16)\n* Univ. of Pennsylvania School of Medicine, Associate Dean for Research (‘02~’11)\n* Philadelphia VA Medical Center, \xa0Associate Chief of Staff for Research (‘02~’11)\n* University of Pennsylvania School of Medicine, Associate Professor of Medicine in Infectious Diseases (‘02~’11)\n* Philadelphia VA Medical Center, Interim Chief of Medicine (‘08~’10)\n* Philadelphia VA Medical Center, Section Chief for Infectious Diseases(‘99~’05)\n* Philadelphia VA Medical Center, Director for HIV/AIDS research (‘99~’06)\n* Tuft\'s University School of Veterinary Medicine, Adjunct Associate Professor in Comparative Medicine(‘96~’99)\n* Boston University School of Medicine, Associate Professor of Medicine (‘90~’99)\n* Inovio Pharmaceuticals, Chief Medical Officer (‘06)\n* New Jersey AIDS Society, Board Member (‘14~’15)\n* Rapid Pathogen Screening, Scientific Advisory Board (‘14~)\n* Examworks (formerly Network Medical Review), Third party reviewer (‘99~’15)\n* NMR, Third party reviewer (‘11~’12)\n* Aries, founding member(‘11~’13)\n[논문]* IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell response. (’20, Journal of Hepatology)* Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets. (’19, Nature Communications)\n* Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease. (’19, HUMAN VACCINES & IMMUNOTHERAPEUTICS)\n* Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial (’19, Lancet Infect Dis)\n* Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. (’18, J Infect Dis.)\n* Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. (‘17 N Engl J Med)\n* Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. (‘17 Hum Vaccin Immulother.)\n* Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. (’17, Sci Rep.)\n* Vaccine development for emerging virulent infectious diseases. (’17, Vaccine)\n* Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. (’94, Lancet)\n* Adult pneumococcal cellulitis: case report and review of the literature. (99’, Clin Inf Dis)\n*Latent infection with Mycobacterium avium as a source for disseminated disease in rhesus macaques. (03’, J Infect Dis)\xa0외\xa0다수의\xa0국제\xa0학술지\xa0논문\xa0발표\n\xa0\n[학회발표]\n* DNA vaccine (GLS-5300) against the MERS-CoV: Results of a Phase I study (’18, WHO-IVI Joint Symposium for MERS-CoV Vaccine Development)\n* Developments in Emerging Infectious Diseases. (’16, International Society for Vaccines)\xa0외\xa0다수의\xa0학회\xa0및\xa0초청강연\xa0발표\n\xa0\n[저서]\xa0\n* Epidemiologic Typing Systems. Society for Healthcare Epidemiology of America (SHEA): A Practical Handbook for Hospital Epidemiologists. (’10)\xa0외\xa0다수의\xa0저서\n최고과학개발책임자\n카\xa0무투마니\xa0(Kar Muthumani)\n전임상시험\xa0지원\n*Madurai Kamaraj University, India.\xa0학사,\xa0석사,\xa0박사(’96)\n*Dept. of Life Sciences, Ben-Gurion University of\nthe Negev, Israel.방문연구원\xa0(’97)\n*Dept. of Biology, Texas A&M University, Texas, USA, Postdoctoral Research Fellow(’97-98)\n*Dept. of Pathology and Lab. Medicine University of Pennsylvania School of Medicine PA-USA, Postdoctoral Research Fellow(’98-’00)\n*Dept. of Pathology and Lab. Medicine, Perelman School of Medicine at the University of Pennsylvania, PA-USA, Research Associate(’00-’04)\n*Pathology and Lab. Medicine, Perelman School of Medicine at the University of Pennsylvania, PA-USA, Senior Research Investigator (’04-’07)\n*Perelman School of Medicine at the University of Pennsylvania, PA, USA. Research Assistant Professor (’08-’15)\n*The Wistar Institute, Philadelphia, PA, USA, Assistant Professor (’16-’19)\n*Director for the laboratory of Emerging Infectious Diseases, The Wistar Institute (’16-’20)\n*Associate Professor, The Wistar Institute, Philadelphia, PA, USA.(’20)\n[논문]\xa0\n*Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y,Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC,Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H,Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J,Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021 Jan 12;12(1):346. PMID: 33436641\n*Singh KS, Sharma R, Reddy PAN, Vonteddu P, Good M, Sundarrajan A, Choi H, Muthumani K, Kossenkov A, Goldman AR, Tang HY, Totrov M, Cassel J, Murphy ME, Somasundaram R, Herlyn M, Salvino JM, Dotiwala F. IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance. Nature. 2021 Jan;589(7843):597-602. PMID: 33361818.\n*Choi H, Kudchodkar SB, Ho M, Reuschel EL, Reynolds E, Xu Z, Bordoloi D, Ugen KE, Tebas P, Kim J, Abdel-Mohsen M, Thangamani S, Weiner DB, Muthumani K. A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. PLoS Negl Trop Dis. 2020 Oct 29;14(10):e0008788. PMID: 33119599\n*Khoshnejad M, Dia Y, Patel A, Xu Z, Zhu X, Yun K, Wojtak K, Qureshi R, Humeau L,Muthumani K, Weiner DB. DNA-Encoded Glutamine Synthetase Enzyme as Ammonia-Lowering Therapeutic for \xa0yperammonemia. Nucleic Acid Ther. 2020 Dec;30(6):379-391. PMID: 32907467.\n*Schultheis K, Pugh HM, Oh J, Nguyen J, Yung B, Reed C, Cooch N, Chen J, Yan J, Muthumani K, Humeau LM, Weiner DB, Broderick KE, Smith TRF. Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity. Hum Vaccin Immunother. 2020 Sep 1;16(9):2165-2175. PMID: 32544376\n[저서]\xa0\n*Chung C, Ugen KE, Sardesai NY, Weiner DB, Muthumani K: Protocols for Developing Novel Chikungunya Virus DNA Vaccines. Methods Mol. Biol. 2016; 1426:311-32: PMID: 27233283.\n\xa0\n[강연]\n*October 2019: “In vivo expression of plasmid encoded IgG for immune check point targets by synthetic enhanced DNA as a new tool for cancer immunotherapy”.International Society for Vaccines, October 2019, Ghent, Belgium.\n*September 2019: “Synthetic nucleic acid antibody prophylaxis (DMAb) + DNA vaccine confers rapid and durable protective immunity against Zika virus challenge”. Elsevier Conference: 13th Vaccine Congress 2019, Bangkok, Thailand.\n*Oct 2018: “Rapid response to Zika vaccine development- Lessons learned, Keystone meeting on Framing the Response to Emerging Virus Infections, Hong Kong.\n*June 2018: “Synthetic nucleic acid antibody prophylaxis (DMAb) + DNA vaccine confers rapid and durable protective immunity against Zika virus challenge” 2nd International Conference on Zika Virus and Aedes related Infections, Tallinn, Estonia.\n기업부설\xa0R&D\xa0연구소\xa0연구소장\n(이사)\n김원일\n전임상\xa0연구개발\xa0총괄\n* \xa0미국\xa0미네소타\xa0주립대학\xa0분자세포생물학\xa0이학박사\xa0(Ph.D.)(’08)\n* \xa0미국\xa0보스턴\xa0어린이병원/하버드의대\xa0혈액종양과\xa0박사후\xa0연구원\xa0 \xa0 (‘08~‘10)\n* \xa0미국\xa0프레데릭국립암연구소\xa0혈액줄기세포섹션\xa0박사후\xa0연구원\xa0 \xa0 (‘10~ ‘16)\n* \xa0미국\xa0세인트주드\xa0어린이연구병원\xa0종양과책임연구원(‘16~‘20)\n* \xa0㈜사이러스테라퓨틱스\xa0상무/연구위원(’20~‘21)\n[논문]\n* \xa0Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, Charlie Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy & Tanja A. Gruber (2023) Proteasome Inhibition Targets the KMT2A Transcriptional Complex. Nature Communications 14:809\n* Moonsup Jeong, Sagar B Kudchodkar, Areum Gil, Bohyun Jeon, Gee Ho Park, Youngran Cho, Hyojin Lee, Mi Sun Cheong, Wonil Kim, Yun-Ho Hwang, Jung-Ah Lee, Heeji Lim, Mi Young Kim, Emran Lallow, Tej Brahmbhatt, Stephen Anthony Kania, Nandita C Jhumur, Jerry W Shan, Jeffrey D Zahn, David I Shreiber, Jonathan Singer, Hao Lin, Erin K Spiegel, Laurent Pessaint, Maciel Porto, Alex Van Ry, Danielle Nase, Swagata Kar, Hanne Andersen, Ian Tietjen, Joel Cas-sel, Joseph Salvino, Luis J Montaner, Young K Park, Kar Muthumani, Christine C Roberts, Joel Maslow (2022) Immune responses of a novel bi-cistronic SARS-CoV-2 DNA vaccine follow-ing intradermal immunization with suction delivery. Frontiers in Virology 2:891540\n* \xa0Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Sridhar Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Krivtsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong (2015) Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res 21(10):2348-58\n* \xa0Wonil Kim, Kimberly D. Klarmann, Jonathan R. Keller (2014) Gfi-1 regulates the erythroid transcription factor network through Id2 repression in murine hematopoietic progenitor cells. Blood 124(10):1586-96\n* \xa0Won-Il Kim, Ilze Matise, Miechaleen D. Diers and David A. Largaespada (2009) RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood 113(5):1086-96\n* \xa0Won-Il Kim (2008) Oncogenic Roles of RAS in Acute Myeloid Leukemia Cooperated with MLL-AF9. Dissertation for Ph.D. degree accomplished in University of Minnesota\n* \xa0Won-Il Kim, Stephen M. Wiesner, and David A. Largaespada (2007) Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells. Experimental Hematology 35(8):1231-9\n* \xa0Tae Yon Kim, Won-Il Kim, Ronald E. Smith and EunDuck P. Kay (2001) Role of p27 (Kip1) in cAMP- and TGF-beta2-mediated antiproliferation in rabbit corneal endothelial cells. Investigative Ophthalmology and Visual Science 42(13):3142-9\n* \xa0Tae Yon Kim, Won-Il Kim, Ronald E. Smith, EunDuck P. Kay (2001). Differential activity of TGF-beta2 on the expression of p27Kip1 and Cdk4 in actively cycling and contact inhibited rabbit corneal endothelial cells. Molecular Vision 7:261-70\n* \xa0Won-Il Kim, Woo-Bok Lee, Kiwon Song, Jinmi Kim (2000). Identification of a putative DEAD-box RNA helicase and a zinc-finger protein in Candida albicans by functional complementation of the S. cerevisiae rok1 mutation. Yeast 16(5):401-9\n\xa0\n[학회발표]\n* 2023 \xa0 Oral presentation on “Nucleotide-based vaccine research and development in GeneOne Life Science” and panel discussion with the topic of “Asia Vaccine Development and Manufacturing Capabilities: Where are We Now” at 5th Edition World Vaccine Asia Congress 2023 in Singapore\n* \xa02019 \xa0 Poster presentation and abstract published with the study title of “KMT2A-rearranged Infant Acute Lymphoblastic Leukemia Cells Undergo ER-Stress-Induced Apoptosis Following Exposure to Proteasome Inhibitors” at 61th America Society of Hematology (ASH) Annual Meeting.\xa0\n* \xa02013 \xa0 Oral presentation with the study of “Gfi-1 regulates the erythroid transcription factor network through Id2 repression in murine hematopoietic progenitor cells” at 55th American Society of Hematology (ASH) Annual Meeting.\n* \xa02008 \xa0 Poster presentation and abstract published with the study title of “A Murine AML Model for the Development of Resistance to NRAS(G12V) Oncogene Repression and/or Ara-C Treatment in Vivo” at 50th American Society of Hematology (ASH) Annual Meeting.\xa0\n* \xa02007 \xa0 Poster presentation and abstract published with the study title of “RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia” at 49th America Society of Hematology (ASH) Annual Meeting.\xa0\n* \xa02006 \xa0 Poster Presentation with the study title of “Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells” at Mouse Models of Cancer in American Association of Cancer Research (AACR).\n* \xa02003 \xa0 Poster presentation with the study title of “The Effect of p27 Expression on the Growth of Rabbit Corneal Endothelial Cells” at 42nd American Society for Cell Biology Annual Meeting.\n\xa0\n[저서]\n* \xa0Kimberly D. Klarmann, Ming Ji, Huajie Li, Ande Satyanarayana, Wonil Kim, Emily Bowers, Bjorg Gudmundsdottir and Jonathan R. Keller (2011) Novel Targets in Myelogenous Leukemia: The Id Family of Proteins. Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, ISBN: 978-953-307-789-5, InTech\xa0\n신약개발본부\n(이사)\n권이주\n임상개발\n총괄\n* \xa0아주대학교\xa0대학원\xa0신경과학\xa0박사(’06)\n* \xa0아주대학교\xa0의료원/아주대학교\xa0의과대학\xa0연구\xa0강사(\'06~\'08)\n* \xa0삼성생명과학\xa0연구소/성균관대학교\xa0의과대학,\xa0박사후\xa0연구원\xa0 \xa0 (\'08~\'11)\n* \xa0미국\xa0Emory University, School of Medicine, Post-doctoral \xa0 \xa0 \xa0Fellow \xa0 \xa0(\'11~\'12)\xa0\n* \xa0미국\xa0University of Rochester, Aab Cardiovascular Research \xa0 \xa0 Institute, Post-doctoral Associate(\'12~\'14)\n* \xa0서울아산병원/울산대학교\xa0의과대학\xa0연구\xa0부교수(\'14~\'15)\xa0\n* \xa0㈜안트로젠, R&D\xa0중앙연구소\xa0책임연구원/부장(\'15~\'16)\n* \xa0㈜지디에프아이브레인셀연구소\xa0CRO, MW & Statistics  \xa0 \xa0Divisions\xa0이사(\'17~\'19)\n* \xa0㈜드림씨아이에스\xa0CRO, Medical Affair Division\xa0이사(\'19)\xa0\n* \xa0올리패스㈜,\xa0임상개발실\xa0이사(\'19~\'22)\n* \xa0진원생명과학㈜,\xa0신약개발본부\xa0이사(\'22~ )\n[논문]*Tissue Tension and Strain as Indicators of Suction-mediated Cutaneous DNA Transfection: A Parametric Study (\'24, Advanced Therapeutics)\n* Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost. (\'23, Vaccine-Elsevier)\n* DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond. (\'23, Vaccines)\n* Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. (\'23, International Journal of Infectious Diseases)\xa0\n\xa0\n* Primary cilia mediate early life programming of adiposity lysosomal regulation in the developing mouse hypothalamus. (\'20, Nature Communications)\n* \xa0B23/Nucleophosmin promotes reconstitution of synaptic path in hippocampus after injury. (\'19, Biochem Biophys Res Commun.)\n* \xa0Akt1-Inhibitor of DNA binding2 is essential for growth cone formation and axon growth and promotes central nervous system axon regeneration. (\'16, eLife)\n* \xa0Leptin elongates hypothalamic neuronal cilia via transcriptional regulation and actin destabilization. (\'15, The Joural of Biological Chemistry)\n* \xa0Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer&apos;s disease. (\'14, Nature Medicine)\n* \xa0HDAC5 interacts with KLF2 and inhibits its transcription in vascular endothelial cells. (\'14, Cardiovascular Research)\n* \xa0SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer\'s disease. (\'12, Journal of Neuroscience)\n* \xa0p48 Ebp1 acts as a downstream mediator of Trk signaling in neurons, contributing neuronal differentiation. (\'11, Neurochemistry international)\n* \xa0PI(3,4,5)P3 regulates the interaction between Akt and B23 in the nucleus. (\'10, BMB reports)\n* \xa0Ribosomal protein S3, a new substrate of Akt, serves as a signal mediator between neuronal apoptosis and DNA repair. (\'10, The Journal of biological chemistry)\n* \xa0Inhibition of neuronal differentiation by Akt-dependent Id2 phosphorylation. (\'09, Journal of Neurochemistry)\n* \xa0Neuronal Polarity:Fate determination of neurite into axon or dendrite. (\'09, KSMCB)\n* \xa0Expression of Disabled 1 suppresses astroglial differentiation in neural stem cells. (\'09, Molecular and cellular neurosciences)\n* \xa0Overexpression of BETA2/NeuroD induces neurite outgrowth in F11 neuroblastoma cells. (\'09, Journal of neurochemistry)\n* \xa0Differential regulation of tyrosine hydroxylase expression by sonic hedgehog. (\'06, Neuroreport)\n* \xa0Activation of the tyrosine hydroxylase promoter by NeuroD in neural stem cell(\'05, Experimental Neurobiology)\n* \xa0The amino acid compositions of formula for children with inherited metabolic disorder. (\'02, Jounal of the Korean Pediatric Society)\xa0\n\xa0\n[학술\xa0활동]\n초빙\xa0강연\n* \xa0Pharmicell Stem Cell Symposium (\'16, Korea)\n* \xa0Korea Academy of Aesthetic Surgery (\'16, Korea)\n* \xa0Hwasun International Vaccine Forum 2022 (’22, Korea)\n세미나\n* \xa0Biomedical Research Center, Asan Institute for Life Sciences(\'15,Asan Medical Center)\n\xa0\n국제학회\xa0발표\n* \xa0Presentation of Annual Meeting of ATVB (\'13, Orlando, USA)\n* \xa0Presentation in 40th Annual Meeting of SFN (\'10, San Diego, USA)\n* \xa0Presentation in 39th Annual Meeting of SFN (\'09, Chicago, USA)\n* \xa0Presentation in Biennial Meeting of the International SFN (\'09, Korea)\n* \xa0Presentation in 35th, Annual Meeting of SFN (\'05, Washington DC, USA)\n* \xa0Presentation in 34th, Annual Meeting of SFN (\'04, San Diego, USA)\n* \xa0Presentation in 16th, International Congress of the IFAA (\'04, Kyoto, Japan)\xa0외\xa0다수의\xa0학회\xa0발표\n임상실험실분석팀장\n크리스틴\xa0로버츠\n(Christine Roberts)\n임상면역평가\n* Lehigh University, Ph.D. Molecular Biology (’94)\n* Lehigh University, Research Assistant (‘94~’01)\n* Merck & Company, Vaccines Basic Research, Merck Co-Op Program, Staff Biochemist (‘01~’03)\n* Merck & Company, Vaccines Basic Research, Research Biochemist (‘03~’05)\n* Merck & Company, Vaccines Basic Research, Senior Research Biochemist (‘05~’08)\n* Merck & Company, Vaccines Basic Research, Research Fellow (‘08~’10)\n* Merck & Company \xa0Director, Vaccine Clinical Assays (‘10~’15)\n[논문] * Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial (\'19, Lancet Infect Dis) * Assay Challenges for Emerging Infectious Diseases: The Zika Experience. (\'18, Vaccines) * Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. (\'18, J Infect Dis.) * Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. (\'17, N Engl J Med.)\xa0외\xa0다수의\xa0국제\xa0학술지\xa0논문발표 [학회발표] * The prevalence of HPV 16/18 among young sexually active Norwegian women. (\'00, 40th ICAAC Meeting)  * Detection of HPV in three different types of specimens of the female genital tract. (\'05, 22nd International Papillomavirus Conference) * HPV detection using a novel real-time HPV Multiplex PCR Assay: Comparison with the Linear Array HPV Genotyping PCR Assay. (\'06, 23rd International Papillomavirus Conference)외\xa0다수의\xa0학회\xa0발표\n3) 연구개발 비용당반기까지 지급된 코로나19 백신 및 만성 C형 간염 치료용 DNA 백신 등의 연구/개발, 자문료, 임상 시료 구입비 등은 아래 표와 같습니다.\n<연결 기준> (기준일 : 2024년 06월 30일) \xa0 \xa0\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 백만원)\n과 \xa0 목\n49기 (당반기)\n제48기\n제47기\n비고\n회계처리\n판매비와 관리비\n3,564\n7,043\n12,147\n-\n개발비(무형자산)\n-\n-\n-\n-\n연구개발비용 계(*1)\n3,564\n7,043\n12,147\n\u3000\n(정부보조금)\n-\n(57)\n(734)\n-\n정부보조금 차감 후 연구개발비용 계\n3,564\n6,986\n11,413\n\u3000\n연구개발비 / 매출액 비율(*2) \xa0 [연구개발비용계÷당기매출액×100]\n21.8%\n17.4%\n23.4%\n-\n(*1) 연구개발비용은 전액 판관비로 계상되어 있으며, 정부 보조금을 차감하기 전의 연구개발비용 지출 총액입니다.\n(*2) 매출액 대비 정부 보조금 차감 후 연구개발비용이 차지하는 비율로 산출하였습니다. \xa0<별도 기준>\n(기준일 : 2024년 06월 30일) \xa0 \xa0\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 백만원)\n과 \xa0 목\n49기 (당반기)\n제48기\n제47기\n비고\n회계처리\n판매비와 관리비\n3,573\n8,741\n12,977\n-\n개발비(무형자산)\n-\n-\n-\n-\n연구개발비용 계(*1)\n3,573\n8,741\n12,977\n\u3000\n(정부보조금)\n-\n(57)\n(734)\n-\n정부보조금 차감 후 연구개발비용 계\n3,573\n8,684\n12,243\n\u3000\n연구개발비 / 매출액 비율(*2) \xa0 [연구개발비용계÷당기매출액×100]\n23.6%\n23.0%\n26.8%\n-\n(*1) 연구개발비용은 전액 판관비로 계상되어 있으며, 정부 보조금을 차감하기 전의 연구개발비용 지출 총액입니다.\n(*2) 매출액 대비 정부 보조금 차감 후 연구개발비용이 차지하는 비율로 산출하였습니다.\n4)\xa0\n연구개발\n\xa0\n실적\n ①\xa0\n연구개발\n\xa0\n진행\n\xa0\n현황\n\xa0\n및\n\xa0\n향후\n\xa0\n계획\n공시\xa0서류\xa0작성기준일\xa0현재\xa0당사가\xa0연구개발\xa0진행\xa0중인\xa0신약의\xa0현황은\xa0다음과\xa0같습니다.\n<\n연구개발\n\xa0\n진행\n\xa0\n총괄표\n>\n구분\n품목\n적응증\n연구시작일\n현재\n\xa0\n진행\n\xa0\n단계\n비고\n단계\n(\n국가\n)\n승인일\n핵산\xa0기반\xa0바이오\xa0신약\nDNA\xa0백신\nGLS-5300\n메르스\xa0예방\n2015년\n임상1/2a상\xa0완료(한국)\n2017년\n공동개발\nGLS-5700\n지카\xa0바이러스\xa0예방\n2016년\n임상1상\xa0완료(푸에르토리코)\n2016년\n공동개발\nGLS-5310\n코로나19\xa0예방\n2020년\n임상1/2a상(한국)\n2020년\n정부보조금\nGLS-6150/GLS-6100\nC형\xa0간염\xa0예방\n2017년\n임상\xa01상\xa0완료(한국)\n2018년/2021년\n정부보조금\nVGX-6150\n만성\xa0C형\xa0간염\xa0치료\n2011년\n임상\xa01상\xa0완료(한국)\n2013년\n공동개발\nGLS-5140\n중증열성혈소판감소증후군\xa0예방\n2015년\n임상\xa01상\xa0IND\xa0자진취하\n\xa0\n및\n\xa0\n추가보완\n\xa0\n자료\n\xa0\n준비\n\xa0\n\xa0\n\xa0-\n정부보조금\n핵산\xa0기반\xa0단백질\xa0및단클론\xa0항체의약품\nGLS-7100,\xa0혈액응고\xa08인자\xa0dRP\nA형\xa0혈우병\xa0치료\n2014년\n신약후보물질\n\xa0-\n\xa0-\nGLS-8000, B형간염\xa0면역글로불린\xa0Plas-mAb\nHBV\xa0감염예방\n2017년\n신약후보물질\n\xa0-\n특허양수\n항염증\n치료\xa0신약\n천연물\xa0유래\xa0성분\nGLS-1200,쓴맛\xa0수용체\xa0신호전달\xa0물질\n항염증제(만성\xa0축농증치료)\n2018년\n임상\xa02상(미국)\n\xa02020년\n라이센스인\n코로나19\xa0감염\xa0예방\xa0약물\n2020년\n임상\xa02상\xa0(미국)\n\xa02020년\n-\n저분자량\xa0화학합성\xa0성분\nGLS-1027\n당뇨병성\xa0신장질환\xa0치료\n2019년\n임상\xa02상\xa0준비(미국)\n-\n-\n코로나19\xa0중증\xa0방지\xa0약물\n2020년\n임상\xa02상(미국),\n임상\xa02상(북마케도니아,\xa0불가리아,\xa0한국)\n임상\xa02상 결과 분석 완료(미국).\xa0국내 식약처에 종료보고서 제출 완료(한국)\n2020년,\n2021년\n-\n\xa0\n(\n가\n)\xa0\n품목\n\xa0: GLS-5300\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\n중동호흡기증후군\xa0예방\n3.\xa0\n작용\n\xa0\n기전\nGLS-5300\xa0접종으로\xa0체내\xa0메르스\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응\xa0및\xa0항체\xa0면역반응이\xa0유도되어,\xa0메르스\xa0바이러스의\xa0감염을\xa0억제하여\xa0예방에\xa0성공할\xa0수\xa0있음.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0백신\xa0대비\xa0백신에\xa0의한\xa0메르스\xa0감염\xa0우려\xa0전무하고, \xa0대장균\xa0발효\xa0및\xa0정제에\xa0의한\xa0백신의\xa0생산으로\xa0생산기간이\xa0단축되고\xa0가격\xa0경쟁력이\xa0우수하며,\xa0주성분인\xa0플라스미드\xa0DNA\xa0특성상\xa0장기\xa0보관이\xa0가능하여\xa0응급\xa0백신으로\xa0개발\xa0용이.\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01상]-글로벌\xa0임상\n임상시험\xa0승인일\xa0:\xa0미국\xa0FDA(2015년\xa011월\xa019일),\xa0임상\xa0시작일\xa0: 2016년\xa01월\xa028일,\xa0진행\xa0국가\xa0:\xa0미국, 1상\xa0임상\xa0예비\xa0결과\xa0발표\xa0(2018년\xa06월\xa027일), 1상\xa0임상\xa0결과\xa0논문게재\xa0(Lancet Infectious Disease, 2019년\xa07월\xa025일).\n[임상\xa01/2a상]-국내\xa0임상\n임상시험\xa0승인일:\xa0국내\xa0식품의약품안전처(2017년\xa09월\xa017일),\xa0임상\xa0시작일: 2018년\xa09월\xa05일, 1/2a상\xa0임상\xa0중간결과\xa0발표(2020년\xa05월), 1/2a상\xa0임상시험\xa0종료(2020년\xa04월\xa024일). \xa0[임상시험결과]\xa0본\xa0임상시험은\xa0GLS-5300 \xa0피내\xa0접종하고\xa0접종\xa0부위에\xa0추가로\xa0전기천공기로\xa0전기충격을\xa0주어\xa0안전성\xa0및\xa0내약성을\xa0평가한\xa0임상시험임. GLS-5300 0.3mg을\xa03회\xa0또는\xa00.6mg 2회,\xa0혹은\xa03회\xa0접종함.\xa0결과\xa0분석을\xa0통해\xa0임상시험\xa0기간\xa0동안\xa0모든\xa0접종군에서\xa0GLS-5300과\xa0관련\xa0있는\xa0중대한\xa0이상\xa0반응은\xa0관찰되지\xa0않았음. 0.3mg\xa0또는\xa00.6mg\xa0용량을\xa0투여한\xa0그룹에서\xa0접종\xa0횟수와\xa0상관없이\xa0두\xa0그룹간\xa0내약성의\xa0차이는\xa0없었으며\xa0백신의\xa0효과가\xa0잘\xa0유지되는\xa0것을확인함.\n6.\xa0\n향후\n\xa0\n계획\n당사와의\xa0계약에\xa0따라\xa0당사에서는\xa0국내\xa01/2a상\xa0임상시험을,\xa0이노비오사는\xa0\xa0임상\xa02상부터\xa0시판허가까지는\xa0공동개발사인\xa0미국\xa0이노비오사가\xa0수행하기로\xa0함.\xa0당사의\xa01/2a\xa0임상시험은\xa0완료됨(2020년\xa04월\xa024일).\xa0이후,\xa0이노비오사에서는\xa0CEPI의\xa0연구비를\xa0지원받아\xa0수행한\xa0임상\xa02상의\xa0초기\xa0데이터\xa0분석\xa0결과에\xa0의하여\xa0중단함(2022년\xa011월\xa017일).\n7.\xa0\n경쟁\n\xa0\n제품\n개발에\xa0성공한\xa0제품은\xa0없으며\xa0전임상과\xa0임상\xa0단계에서\xa0개발\xa0중\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\n- \xa0 A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates (Sci Transl Med. 2015)\n- \xa0 Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial (Lancet Infect Dis. 2019)\n9.\xa0\n시장\n\xa0\n규모\n초기임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\xa0\n공동\n\xa0\n개발\n미국\xa0이노비오사와\xa0메르스\xa0백신의\xa0공동연구계약을\xa0체결하고\xa0공동개발(2015년\xa05월\xa027일).\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음.\n12.\xa0\n기타\n\xa0\n사항\n- \xa0전염병대비혁신연합(CEPI)은\xa0이노비오사와\xa0계약을\xa0체결하여\xa0전\xa0세계\xa0응급\xa0비축용\xa0백신\xa0개발\xa0지원\xa0(2018년\xa04월\xa012일) :\xa0당사는\xa0자회사인\xa0VGXI를\xa0통해\xa0전\xa0세계\xa0메르스\xa0응급\xa0백신의\xa0생산과\xa0공급을\xa0담당.\n-\xa0국내에서\xa0메르스\xa0DNA\xa0백신의\xa0개발\xa0및\xa0국가기관에\xa0응급\xa0백신을\xa0공급하기\xa0위해, 2016년\xa012월\xa07일\xa0국제백신연구소(IVI)로부터\xa0개발비\xa0전액을\xa0지원받음.\n\xa0\n(\n나\n)\xa0\n품목\n\xa0: GLS-5700\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\n지카(Zika)\xa0바이러스\xa0감염\xa0예방\n3.\xa0\n작용\n\xa0\n기전\nGLS-5700\xa0접종으로\xa0체내\xa0지카\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응\xa0및\xa0항체\xa0면역반응이\xa0유도되어,\xa0지카\xa0바이러스의\xa0감염을\xa0억제하여\xa0예방에\xa0성공할\xa0수\xa0있음.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0백신\xa0대비\xa0백신에\xa0의한\xa0지카\xa0바이러스\xa0감염\xa0우려\xa0전무하고, \xa0대장균\xa0발효\xa0및\xa0정제에\xa0의한\xa0백신의\xa0생산으로\xa0생산기간이\xa0단축되고\xa0가격\xa0경쟁력이\xa0우수하며,\xa0주성분인\xa0플라스미드\xa0DNA\xa0특성상\xa0장기\xa0보관이\xa0가능하여\xa0응급\xa0백신으로\xa0개발\xa0용이.\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01상]-미국,캐나다\n임상시험\xa0승인일\xa0:\xa0미국\xa0FDA(2016년\xa06월\xa020일),\xa0임상\xa0시작일\xa0: 2016년\xa07월\xa027일,\xa0진행\xa0국가\xa0:\xa0미국,캐나다, 1상\xa0임상\xa0결과\xa0발표\xa0(2017년\xa010월\xa010일)\n[임상\xa01b상]-푸에르토리코(미국령)\n임상시험\xa0승인일\xa0:\xa0미국\xa0FDA(2016년\xa08월\xa030일),\xa0임상시험\xa0대상자\xa0모집등록\xa0완료: 2017년\xa06월\xa016일,\xa0임상시험\xa0종료: 2018년\xa06월.[임상시험\xa0결과] GLS-5700\xa0백신을\xa01mg\xa0단\xa0회\xa0피내\xa0투여\xa0혹은\xa02mg 2회\xa0피내\xa0투여함.\xa0두\xa0그룹\xa0모두에서\xa0접종\xa0부위에\xa0이상\xa0반응이\xa0일시적으로\xa0발현했지만\xa0경미했고,\xa0두\xa0그룹에서\xa0용량에\xa0따른\xa0발현의\xa0차이는\xa0없었음.\xa0또한, GLS-5700과\xa0관련\xa0있는\xa0중대한\xa0이상\xa0반응은\xa0관찰되지\xa0않았고,\xa0두\xa0그룹간\xa0내약성의\xa0차이는\xa0없었으며\xa0백신의\xa0효과가\xa0잘\xa0유지되는\xa0것을\xa0확인함.\xa0\n6.\xa0\n향후\n\xa0\n계획\n임상\xa02상부터\xa0시판허가까지는\xa0공동개발사인\xa0미국\xa0이노비오사가\xa0수행하기로\xa0계약하였으므로\xa0당사는\xa0임상\xa01상과\xa01b상\xa0완료\xa0후\xa0추가\xa0임상은\xa0중단함.\n7.\xa0\n경쟁\n\xa0\n제품\nNIH/VRC 705\xa0임상\xa02상\xa0완료됨. NIAID(미국국립알레르기·감염병연구소)/ZPIV, NIAID(미국국립알레르기\xa0감염병연구소)/rZIKV, Moderna TX/mRNA-1893\xa0등\xa0임상\xa01상\xa0대상자\xa0모집\xa0중\xa0이거나\xa0완료됨.\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nSafety and Immunogenicity of an Anti-Zika Virus DNA Vaccine -- Preliminary Report (2017, The \xa0New England Journal of Medicine)\n9.\xa0\n시장\n\xa0\n규모\n초기\xa0임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\xa0\n공동\n\xa0\n개발\n미국\xa0이노비오사와\xa0지카\xa0바이러스\xa0DNA\xa0백신의\xa0공동연구계약을\xa0체결하고\xa0공동개발(2016년\xa01월\xa022일).\xa0\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n\xa0\n(\n다\n)\xa0\n품목\n\xa0: GLS-5310\xa0\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\n코로나19\xa0감염증\xa0예방\n3.\xa0\n작용기전\n정상인에게\xa0GLS-5310\xa0접종으로\xa0체내\xa0SARS-CoV-2\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응과\xa0항체\xa0면역반응이\xa0유도되어, \xa0SARS-CoV-2\xa0바이러스의\xa0감염을\xa0억제함으로써\xa0코로나19\xa0감염증을\xa0예방.\n4.\xa0\n제품의\n\xa0\n특성\n약독화\xa0생백신\xa0대비\xa0DNA\xa0백신은\xa0감염의\xa0우려가\xa0없음,\xa0바이러스에\xa0대한\xa0항체\xa0면역반응과\xa0더불어\xa0강력한\xa0세포성\xa0면역\xa0반응\xa0유도할\xa0수\xa0있음.\n5.\xa0\n진행\n\xa0\n경과\n[신약후보물질\xa0연구]후보물질\xa0도출연구\xa0착수: 2020년\xa02월\xa0후보물질\xa0도출\xa0및\xa0항원\xa0발현\xa0확인\xa0: 2020년\xa04월\xa0VGXI사\xa0GMP\xa0생산공정\xa0개발\xa0및\xa0임상용\xa0백신\xa0생산착수: 2020년\xa06월,\xa0후보물질을\xa0마우스에\xa0접종한\xa0후우수한\xa0항원\xa0특이적\xa0T세포\xa0면역반응과\xa0항원\xa0특이적\xa0결합\xa0항체반응이\xa0유도되는\xa0것을\xa0확인: 2020년\xa07월\xa0후보물질을\xa0마우스에\xa0접종한\xa0후\xa0우수한\xa0항원\xa0특이적\xa0T세포\xa0면역반응과\xa0항원\xa0특이적\xa0결합\xa0항체반응,중화항체\xa0생성을\xa0확인:\xa02020.9,\xa0\n임상시험용\n\xa0\n백신의\n\xa0cGMP\xa0\n생산함\n.\xa0\n이를\n\xa0\n실험동물에서\n\xa0\n임상\n\xa0\n적용과\n\xa0\n동일한\n\xa0\n트여\n\xa0\n경로로\n\xa0\n접종해서\n\xa0\n용량\n\xa0\n증량에\n\xa0\n따른\n\xa0\n면역원성\n\xa0\n차이를\n\xa0\n평가한\n\xa0\n후\n\xa0\n\xa0\n독성\xa0연구를\xa0착수: 2020년\xa012월\xa07일\xa0국내\xa0식품의약품안전처로부터\xa01/2a상\xa0임상\xa0승인을\xa0받음: 2020년\xa012월\xa018일\xa0고대구로병원\xa0임상시험\xa0계약을\xa0체결: 2020년\xa012월\xa031일\xa0첫\xa0번째\xa0대상자의\xa0접종을\xa0완료.\n2021년\xa01월\xa021일\xa0고용량군의\xa0등록을\xa0시작하여, 2021년\xa03월\xa04일\xa0임상\xa01상\xa0연구\xa0대상자\xa045명의\xa0등록을\xa0완료하고, 2021년\xa05월\xa0모든\xa0대상자의\xa0접종이\xa0완료되었고\xa02021년\xa07월\xa08일,\xa0임상\xa01상\xa0중간\xa0분석\xa01차\xa0결과를\xa0확인하고\xa0자료안전성모니터링위원회\xa0심의를\xa0통과하여\xa0임상2a상에\xa0진입,\xa0피내\xa0접종과\xa0비강\xa0내\xa0접종을\xa0병용하는\xa0임상시험을\xa0미국에서\xa0수행하기위해, 2020년\xa01월19일\xa0미국\xa0FDA에\xa0임상시험계획\xa0승인\xa0신청을\xa0하여\xa02021년\xa07월\xa027일\xa0임상\xa0승인을\xa0받음. 2021년\xa09월\xa06일, \xa0국가임상시험지원재단과\xa0코로나19백신\xa0임상2a상\xa0대상자\xa0모집지원\xa0협약을\xa0체결. 2023년\xa03월\xa0자체\xa0개발\xa0흡인작용\xa0피내\xa0접종기\xa0진덤(GeneDerm)을\xa0이용한\xa0코로나19 DNA\xa0백신(GLS-5310)의\xa0안전성\xa0및\xa0면역원성에\xa0대한\xa0임상\xa01상\xa0결과를\xa0국제감염병학회\xa0(International Society for Infectious Diseases, ISID)\xa0학술지인\xa0국제감염질환저널(International Journal of Infectious Diseases)에\xa0게재. 2023년\xa05월\xa0SARS-CoV-2를포함한\xa0전염병\xa0대비를\xa0위한\xa0DNA\xa0백신\xa0관련\xa0내용의\xa0리뷰\xa0논문을\xa0Vaccines\xa0학술지에\xa0게재. 2023년\xa06월\xa0임상\xa01상\xa0분석\xa0결과\xa0중에서\xa0GLS-5310 DNA\xa0기초접종\xa0후\xa0mRNA\xa0백신을\xa0\xa0추가\xa0접종한\xa0대상자들에\xa0대한\xa0면역원성\xa0결과를\xa0Vaccine (Elsevier)\xa0학술지에\xa0게재.2021년\xa07월\xa022일,\xa0코로나19 DNA\xa0백신인\xa0GLS-5310의\xa0백신\xa0조성물\xa0특허의\xa0국내\xa0및\xa0PCT\xa0출원을\xa0완료. 2021년\xa08월\xa027일, \xa0DNA\xa0백신의\xa0흡인작용\xa0피내\xa0접종기인\xa0Gene-Derm의\xa0흡인기\xa0모듈에\xa0대한\xa0개량\xa0특허를\xa0국내에\xa0출원, 2022년\xa011월\xa0 10일과\xa011월\xa011일\xa0PCT\xa0출원을\xa0완료. 2021년\xa010월\xa0GLS-5310이\xa0햄스터\xa0공격\xa0감염모델에서\xa0야생형및\xa0베타\xa0변이\xa0코로나19\xa0바이러스\xa0완벽하게\xa0감염\xa0예방함을\xa0확인. 2021년\xa011월\xa05일, DNA\xa0백신의\xa0흡인작용\xa0피내접종기GeneDerm의\xa0플랫폼\xa0개발\xa0연구\xa0결과를\xa0사이언스의\xa0자매지Science Advances(사이언스\xa0어드밴시스)에\xa0게재. 2023년\xa01월\xa0미국\xa0뉴저지\xa0주립대학인\xa0럿거스(Rutgers)\xa0대학\xa0연구진과\xa0공동연구로\xa0진행된\xa0자체\xa0개발\xa0흡인작용\xa0피내\xa0접종기\xa0진덤(GeneDerm)의\xa0약물전달\xa0메커니즘\xa0연구\xa0결과를\xa0국제학술지\xa0약물\xa0전달\xa0프론티어스(Frontiers in Drug Delivery)에\xa0게재.  2022년\xa01월\xa03일\xa0미국\xa0FDA로부터\xa0코로나19\xa0백신\xa0접종자들을\xa0대상으로\xa0GLS-5310을\xa0부스터\xa0샷으로\xa0접종하는\xa0임상시험의\xa0승인.\xa0지난\xa02021년\xa07월\xa027일\xa0기\xa0승인을\xa0받은\xa0임상시험\xa0계획서에\xa0대해\xa0계획을\xa0변경하여\xa0승인을\xa0득한\xa0것으로,\xa0미국에서\xa0mRNA\xa0백신과\xa0아데노바이러스\xa0전달체\xa0백신을\xa0접종한\xa0대상자에게\xa0Gene- Derm\xa0흡인압력을\xa0이용한\xa0피내\xa0접종군과\xa0피내\xa0접종\xa0및\xa0코\xa0스프레이를\xa0이용한\xa0비강\xa0내\xa0접종을\xa0병용한\xa0접종군을\xa0비교.[임상시험\xa0결과]\xa0\n[1상]\xa0임상시험\xa0기간\xa0동안\xa0중대한\xa0이상\xa0반응이나\xa0중대한\xa0약물\xa0이상\xa0반응\xa0또는\xa0시험약\xa0투약\xa0중단을\xa0유도한\xa0TEAE는\xa0단\xa0한\xa0건도\xa0발생하지\xa0않음.\n[2a상]\xa0임상시험\xa0기간\xa0동안\xa0Grade 4에\xa0해당하는\xa0TEAE\xa0발현은\xa0없었고,\xa0중대한\xa0이상\xa0반응\xa0또는\xa0특별\xa0관심\xa0이상\xa0반응은\xa0단\xa0한\xa0건도\xa0발생하지\xa0않음.\xa0\n6.\xa0\n향후\n\xa0\n계획\n기초\xa0백신\xa0접종을\xa0위한\xa0대상자\xa0모집이\xa0현\xa0상황에서는\xa0불가함.\xa0추가접종(부스터\xa0샷)의\xa01상\xa0임상시험을\xa0미국에서진행\xa0중이며,\xa0부스터\xa0샷\xa0접종\xa0여부에\xa0대한\xa0임상\xa0결과를\xa0분석,\xa0평가하고자\xa0함. \xa0 \xa0\n7.\xa0\n경쟁\n\xa0\n제품\nDNA\xa0백신(없음). mRNA\xa0백신(큐라티스/QTP104,\xa0아이진/EG-COVID,\xa0에스티팜/STP2104),\xa0합성항원\xa0백신(SK바이오\xa0사이언스/GBP510,\xa0유바이오로직스/EuCorVac-19)\xa0등\xa0(국내\xa02023년\xa05월\xa0기준)\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\n- Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-C oV-2 followed by \xa0 \xa0 \xa0administration of an mRNA vaccine heterologous boost. (Vaccine-Elsevier, 2023, 06)\n- DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond. Vaccines. (Vaccines, 2023, 05)\n- Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the  \xa0 GeneDerm suction device. (Int J Infect Dis., 2023, 03)\n- Molecular distribution in intradermal injection for transfer and delivery of therapeutics. (Front. Drug Deliv., \xa0 \xa02023, 01)\n9.\xa0\n시장\n\xa0\n규모\n비록\xa0긴급\xa0사용허가를\xa0받아\xa0시판\xa0중인\xa0제품이\xa0존재하지만,\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\n공동\n\xa0\n개발\n질병관리본부\xa0국립보건연구원\xa0용역연구개발(2020년\xa04월).\n11.\xa0\n정부\n\xa0\n보조금\n- 2020년\xa03월\xa027일\xa0<2020년도\xa0질병\xa0관리본부\xa0긴급\xa0현안\xa0지정\xa0학술연구개발\xa0용역과제>인\xa0""핵산백신\xa0플랫폼을\xa0활용한\xa0코로나19\xa0백신\xa0후보물질\xa0개발\xa0사업""에\xa0우선\xa0순위\xa0협상대상자로\xa0선정.\xa0(2020년\xa04월부터\xa02020년\xa012월까지\xa0145백만원을\xa0\xa0지원받음)\n- 2021년\xa02월\xa04일,\xa0코로나19백신인\xa0GLS-5310의\xa01/2a상\xa0임상개발\xa0비용인\xa098억원중\xa073억원의\xa0연구비를\xa0정부로부터\xa0지원을\xa0받는\xa0협약을\xa0""코로나19\xa0치료제\xa0백신\xa0신약개발사업단""과\xa0체결.- 2023년\xa01월\xa05일\xa0연구비\xa0정산\xa0결과\xa0\'계열사\xa0등으로\xa0법인이\xa0분리되어\xa0있으나\xa0인적,\xa0물적\xa0구분이\xa0명확하지\xa0아니한\xa0기관간\xa0거래\'라는\xa0판단에\xa0의해\xa0정부\xa0지분액\xa02,518백만원에\xa0대한\xa0회수\xa0처분함.\xa0현재\xa0처분에\xa0대한\xa0취소\xa0소송진행\xa0중임.\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n\xa0\n(\n라\n)\xa0\n품목\n\xa0: GLS-6150/GLS-6100\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\nC형\xa0간염\xa0예방\n3.\xa0\n작용\n\xa0\n기전\n정상인(또는\xa0만성\xa0C형\xa0간염\xa0완치자)에게\xa0GLS-6150/GLS-6100\xa0접종으로\xa0체내\xa0HCV\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응\xa0이\xa0유도되어, HCV\xa0바이러스의\xa0감염\xa0및\xa0재감염을\xa0억제하여\xa0예방에\xa0성공할\xa0수\xa0있음.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0치료제로\xa0완치된\xa0만성\xa0C형\xa0간염\xa0환자나\xa0고위험\xa0정상인을\xa0대상으로\xa0HCV\xa0감염\xa0및\xa0재감염을\xa0예방.\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01상]- GLS-6150 (C형\xa0간염\xa0완치자\xa0대상)\n임상시험\xa0승인일\xa0:\xa0국내\xa0식품의약품안전처(2018년\xa02월\xa05일),\xa0임상\xa0시작일\xa0: 2018년\xa09월\xa04일, 임상\xa0종료일: 2020년\xa05월\xa011일\xa0진행\xa0국가\xa0:\xa0한국,\xa0임상\xa0결과\xa0보고서\xa0최종본\xa0확보.(2022년\xa012월\xa08일)\n[임상\xa01상]- GLS-6100 (정상인)\n임상시험\xa0승인일:\xa0국내\xa0식품의약품안전처(2021년\xa05월\xa020일)과제\xa0후속지원이\xa0없어\xa0개발\xa0종료.(2022년\xa012월)[임상시험\xa0결과] GLS-6150을\xa0건강한\xa0성인\xa0및\xa0항\xa0바이러스제\xa0치료\xa0후\xa0C형\xa0간염\xa0완치자들을\xa0대상으로\xa0접종하였을\xa0때\xa0내약성이\xa0양호하였고,\xa0각\xa0용량을\xa03회\xa0또는\xa04회\xa0접종\xa0시에도\xa0안전성에\xa0위배되는\xa0특이\xa0사항은\xa0관찰되지\xa0않음.\xa0\n6.\xa0\n향후\n\xa0\n계획\n보건복지부의\xa0후속\xa0과제\xa0지원\xa0계획에\xa0따라\xa0GLS-6100(고위험\xa0정상인\xa0대상)\xa0임상시험\xa0추진\xa0계획이었으나,\xa0이후\xa0과제에\xa0대한\xa0후속\xa0지원이\xa0없어\xa0개발\xa0종료함.\n7.\xa0\n경쟁\n\xa0\n제품\n- NIAID, ReiThera (임상\xa02상)\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nPreclinical evaluation of multi-antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection (2017년, Scientific Reports)\n9.\xa0\n시장\n\xa0\n규모\n초기\xa0임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\n공동\n\xa0\n개발\n미국\xa0이노비오사와\xa0연구계약을\xa0체결하여\xa0아시아\xa0지역\xa0독점개발\xa0권리\xa0확보\xa0(2011년\xa010월\xa07일)\n11.\xa0\n정부\n\xa0\n보조금\n보건복지부의\xa0기술개발사업\xa0면역백신\xa0개발\xa0과제로\xa0선정(2017년\xa06월부터\xa02020년\xa012월까지\xa03,415백만원을\xa0지원받고\xa0있음).\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n\xa0\n(\n마\n)\xa0\n품목\n\xa0: VGX-6150\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\n만성\xa0C형\xa0간염\xa0환자의\xa0면역치료\n3.\xa0\n작용\n\xa0\n기전\n만성\xa0C형\xa0간염\xa0환자에\xa0VGX-6150\xa0접종으로\xa0체내\xa0HCV\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응이\xa0유도되어, HCV\xa0바이러스에\xa0감염된\xa0세포를\xa0제거하거나\xa0HCV\xa0바이러스\xa0\xa0방출을\xa0억제하여\xa0만성\xa0C형\xa0간염을\xa0치료.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0만성\xa0C형\xa0간염\xa0면역치료제\xa0대비\xa0부작용이\xa0없고, DAA\xa0등의\xa0항바이러스\xa0의약품\xa0대비\xa0면역기억작용으로\xa0지속적인\xa0만성\xa0C형\xa0간염\xa0억제\xa0효과를\xa0보임,\xa0바이러스\xa0항원의\xa0변이에\xa0대비하기\xa0위해,\xa0공통서열\xa0항원을\xa0도출하여\xa0백신을\xa0디자인함.\xa0\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01상]-한국\n임상시험\xa0승인일:\xa0국내\xa0식품의약품안전처(2013년\xa010월\xa08일),\xa0진행\xa0국가:\xa0한국, 임상\xa0결과\xa0발표: 2020년\xa02월\xa020일 [임상시험\xa0결과]\xa0\n- VGX-6150을\xa0만성\xa0C형\xa0간염\xa0환자를\xa0대상으로\xa0단계적으로\xa0증량하였을\xa0때\xa0내약성이\xa0양호하였고,\xa0모든\xa0용량군에서\xa0안전성에\xa0위배되는\xa0특이\xa0사항은\xa0관찰되지\xa0않음.\n- VGX-6150을\xa0만성\xa0C형\xa0간염\xa0환자\xa0및\xa0표준치료에\xa0실패한\xa0환자를\xa0대상으로\xa0단계적\xa0증량\xa0이후최고용량인\xa06mg을\xa0추가\xa0투여하였을\xa0때,\xa0내약성이\xa0우수하고\xa0안전성\xa0측면에서\xa0양호한\xa0임상시험용의약품으로\xa0평가됨.\xa0\n6.\xa0\n향후\n\xa0\n계획\n2상\xa0임상\xa0단계의\xa0진입을\xa0보류.VGX-6150의\xa0임상\xa0연구\xa0중간\xa0결과를\xa0이용하여\xa0GLS-6150과\xa0GLS-6100에\xa0대한\xa0보건복지부기술개발사업단\xa0주관\xa0과제로\xa0신청,\xa0선정되어\xa0본\xa0VGX-6150은\xa0임상\xa0개발을\xa0중단함.\xa0\n7.\xa0\n경쟁\n\xa0\n제품\nChron Tech Pharma (임상\xa02상)-임상\xa0실패, NIAID/AdCh3NSmut1, MVA-NSmut(임상\xa01/2상)\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\n- \xa0 Preclinical evaluation of multi-antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection (2017년, Scientific Reports)\n- \xa0 IFNL3- adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus- specific T-cell response. (\'20, Journal of Hepatology)\n9.\xa0\n시장\n\xa0\n규모\n초기\xa0임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\xa0\n공동\n\xa0\n개발\n미국\xa0이노비오사와\xa0연구계약을\xa0체결하여\xa0아시아\xa0지역\xa0독점개발권리\xa0확보(2011년\xa010월\xa07일).\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n\xa0\n(\n바\n)\xa0\n품목\n\xa0: GLS-5140\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- DNA\xa0백신\n2.\xa0\n적응증\n중증열성혈소판감소증후군\xa0예방\n3.\xa0\n작용\n\xa0\n기전\n정상인에게\xa0SFTS DNA\xa0백신\xa0접종으로\xa0체내\xa0SFTS\xa0바이러스\xa0특이적\xa0T세포\xa0면역반응과\xa0항체\xa0면역반응이\xa0유도되어, \xa0SFTS\xa0바이러스의\xa0감염을\xa0억제함으로써\xa0중증열성혈소판감소증후군을\xa0예방.\n4.\xa0\n제품의\n\xa0\n특성\n약독화\xa0생백신\xa0대비\xa0DNA\xa0백신은\xa0감염의\xa0우려가\xa0없음,\xa0바이러스에\xa0대한\xa0항체\xa0면역반응과\xa0더불어\xa0강력한\xa0세포성\xa0면역반응\xa0유도할\xa0수\xa0있음.\n5.\xa0\n진행\n\xa0\n경과\n[신약후보물질\xa0연구]-\xa0\n후보물질\n\xa0\n도출연구\n\xa0\n착수\n: 2015\n년\n\xa012\n월\n,\xa0\n후보물질\n\xa0\n효능평가\n\xa0\n완료\n\xa0\n후\n\xa0\n결과\n\xa0\n논문게재\n(Nature Communications 2019).\n-\xa0\n전임상연구\n\xa0\n완료\n: 2020\n년\n\xa010\n월\n\xa0\n실험동물에서\n\xa0\n백신\n\xa0\n후보물질\n\xa0\n선정\n\xa0\n및\n\xa0\n용량\n\xa0\n용법\n\xa0\n최적화\n\xa0\n연구.\n-\xa0\n제\n1\n상\n\xa0\n임상시험\n:\xa0\n임상시험\n\xa01\n상\n\xa0\n계획\n\xa0\n하에\n\xa0\n식품의약품안전처\n\xa0\n사전\n\xa0\n상담을\n\xa03\n차례\n\xa0\n진행\n(2022\n년\n\xa08\n월\n\xa031\n일\n(1\n차\n), 2022\n년\n\xa012\n월\n\xa05\n일\n(2\n차\n) , 2023\n년\n\xa06\n월\n\xa07\n일\n(3\n차\n)), 2023\n년\n\xa011\n월\n\xa08\n일\n\xa0\n제\n\xa01\n상\n\xa0\n임상시험을\n\xa0\n위한\n\xa0IND\xa0\n자료를\n\xa0\n식품의약품안전처에\n\xa0\n제출\n,\xa0\n\xa0\n2024\n년\n\xa01\n월\n\xa017\n일\n\xa0\n자진취하\n\xa0\n결정\n.\xa0\n해당\n\xa0\n임상시험은\n\xa0\n전세계적으로\n\xa0\n전례없는\n\xa0\n최초\n\xa0\n시험이며\n\xa0\n임상자료\n\xa0\n부재\n\xa0\n등의\n\xa0\n이유로\n\xa0\n식약처에서\n\xa0IND\xa0\n보완자료를\n\xa0\n추가\n\xa0\n제출할\n\xa0\n것을\n\xa0\n요구하여\n\xa0\n결정하였음\n.\n\xa0\n6.\xa0\n향후\n\xa0\n계획\n국내\xa01상\xa0임상시험\xa0IND\xa0승인\xa0후\xa0단일\xa0임상시험\xa0실시기관에서\xa0착수\xa0예정임.\n7.\xa0\n경쟁\n\xa0\n제품\n임상용\xa0DNA\xa0백신에\xa0대해\xa0국내외\xa0경쟁제품\xa0없음.\xa0물질\xa0발굴\xa0단계이거나\xa0비임상\xa0연구\xa0단계에서\xa0개발\xa0중이며,\xa0개발사\xa0별\xa0백신\xa0유형은\xa0아래\xa0표에\xa0정리\n백신명\n개발사\n백신\xa0유형\n개발\xa0단계(2023년\xa0기준)\nSFTSV subunit\xa0백신\n전북대학교\xa0산학협력단,\xa0㈜큐라티스\n재조합\xa0단백질과\xa0\n신규\xa0면역증강제\xa0혼합물\n후보물질\xa0검증\nSFTSV\xa0약독화/불활화\xa0백신\n충북대학교\xa0산학협력단,\xa0아이디\xa0바이오㈜\n약독화\xa0바이러스\xa0및\xa0불활화\xa0바이러스\xa0백신\n후보물질\xa0검증\xa0및유효성\xa0평가\n약독화\xa0재조합\xa0SFTSV\xa0백신\n서울대학교\xa0산학협력단,\xa0바이로큐어㈜\n약독화\xa0재조합\xa0SFTS\xa0백신\n비임상\xa0연구\nSFTS mRNA\xa0백신\n모더나\n(국립감염병연구소)\nmRNA\xa0백신\n공동연구협력\xa0협약체결\nSFTS mRNA\xa0백신\n에스티팜\nmRNA\xa0백신\n비임상\xa0연구\nSFTS\xa0예방\xa0DNA\xa0백신\n진원생명과학(주),\n한국과학기술원\nDNA\xa0백신\n1상\xa0임상\xa0IND\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\n- Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease (2019, Human Vaccines & Immunotherapeutics) - Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets (Nature Communications, 2019)\n9.\xa0\n시장\n\xa0\n규모\n초기\xa0개발단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\n공동개발\n한국과학기술원과\xa0복지부\xa0국책연구개발과제에\xa0참여하여\xa0공동개발(2015년\xa012월).\n11.\xa0\n정부\n\xa0\n보조금\n보건복지부의\xa0기술개발사업\xa0면역백신개발\xa0과제로\xa0선정(2015년\xa012월부터\xa02019년\xa011월까지180백만원을\xa0지원받았음),\xa0보건복지부\xa0백신실용화기술개발사업의\xa0미래\xa0대응\xa0미해결\xa0감염병\xa0신규\xa0백신\xa0개발\xa0분야의\xa0지원\xa0과제로\xa0선정되어\xa0임상시험\xa0승인까지의\xa0연구개발비용을\xa0지원받게\xa0되었음(2020년\xa010월부터\xa02022년\xa012월까지).\xa0협약\xa0종료(2023년\xa012월\xa031일).\n12.\xa0\n기타\n\xa0\n사항\n중증열성혈소판감소증후군\xa0예방\xa0DNA\xa0백신에\xa0대한\xa0특허\xa0출원\xa0(대한민국\xa0특허청)\xa0\n출원번호/일자: 10-2018-0074418/2018년\xa06월\xa028일2019년\xa06월\xa026일\xa0해외\xa0특허\xa0출원을\xa0위해\xa0특허\xa0협력조약(PCT)를\xa0출원\n2020년\xa02월\xa04일\xa0대한민국\xa0특허\xa0등록\xa0\xa0\n\xa0\n2024년\xa04월\xa02일 일본 특허등록\n\xa0\n(\n사\n)\xa0\n품목\n\xa0: GLS-7100\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0-\xa0혈액응고\xa08인자\xa0dRP\n2.\xa0\n적응증\nA형\xa0혈우병(8인자\xa0결핍증)\xa0치료\n3.\xa0\n작용\n\xa0\n기전\n혈액응고\xa08인자의\xa0돌연변이로\xa0인한\xa0A형\xa0혈우병\xa0환자에게\xa0핵산\xa0기반\xa0혈액응고\xa08인자\xa0dRP을\xa0투여하면,\xa0투여\xa0부위와\xa0간에서\xa0발현\xa0분비된\xa0단백질\xa0치환\xa0목적의\xa0치료\xa0물질이\xa0다른\xa0응고인자들과\xa0상호작용하여\xa0혈액응고\xa0기작이\xa0원활하게\xa0회복되도록\xa0함으로써\xa0A형\xa0혈우병을\xa0치료.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0혈액응고\xa08인자\xa0단백질의약품의\xa0경우\xa0반감기가\xa0짧은\xa0이유로\xa02-3일에\xa0한번\xa0씩\xa0주사해야\xa0하는\xa0단점이\xa0있지만,\xa0핵산\xa0기반\xa0혈액응고\xa08인자는\xa01회\xa0투여로\xa0체내\xa0지속\xa0발현\xa0효과를\xa0기대할\xa0수\xa0있어\xa0투여회수를\xa0줄일\xa0수\xa0있음.기존\xa0혈액응고\xa08인자\xa0단백질\xa0약제\xa0투여\xa0시\xa0항체\xa0생성으로\xa0인한\xa0저항성이\xa0부작용\xa0증가\xa0및\xa0약효\xa0감소로\xa0나타나는\xa0문제가\xa0있지만,\xa0핵산\xa0기반\xa0치료제의\xa0경우는\xa0체내에서\xa0혈액응고\xa08인자를\xa0생성하므로\xa0이러한\xa0저항성\xa0문제가나타날\xa0가능성이\xa0낮고\xa0전달체를\xa0이용하여\xa0간에서\xa0생성되도록\xa0유도할\xa0수\xa0있으므로\xa0보다\xa0효율적인\xa0효능을\xa0기대할\xa0수\xa0있음.\xa0현재\xa0임상\xa0개발\xa0중인\xa0타사\xa0바이러스\xa0운반체\xa0이용\xa0치료제의\xa0경우\xa0바이러스\xa0벡터에\xa0대한\xa0면역반응으로\xa0인하여\xa0반복적인\xa0투여가\xa0어려운\xa0반면,\xa0핵산\xa0기반\xa0혈액응고\xa08인자\xa0의약품의\xa0경우\xa0바이러스\xa0벡터에\xa0대한\xa0면역반응이\xa0없어\xa0반복적인\xa0투여가\xa0가능.또한,\xa0유전자\xa0치환\xa0목적으로\xa0사용하는\xa0혈액응고\xa08인자\xa0바이러스\xa0벡터의\xa0경우에\xa0매우\xa0비싼\xa0약가가\xa0책정되어\xa0치료제로\xa0사용하기에\xa0경제적인\xa0부담이\xa0매우\xa0높지만,\xa0핵산\xa0기반\xa0혈액응고\xa08인자는\xa0상대적으로\xa0저렴한\xa0가격에\xa0치료받을\xa0수\xa0있음.\n5.\xa0\n진행\n\xa0\n경과\n[신약\xa0후보\xa0물질\xa0연구]\n후보물질\xa0도출연구\xa0착수: 2014년\xa010월,\xa0후보물질\xa0제작\xa0완료/\xa0혈액응고\xa08인자의\xa0체내\xa0생성량과\xa0활성을\xa0높이기\xa0위한\xa0후보물질\xa0개선연구\xa0진행\xa0중.\n코로나19\xa0연구개발에\xa0집중하기\xa0위해\xa0추가적인\xa0후보물질\xa0개선연구를\xa02022년\xa0하반기까지\xa0잠정\xa0연기. 2023년\xa0상반기부터\xa0핵산\xa0기반\xa0혈액응고\xa08인자\xa0후보물질\xa0개선연구\xa0진행.\n6.\xa0\n향후\n\xa0\n계획\n혈우병\xa0동물모델에서\xa0개선된\xa0후보물질의\xa0효능평가\xa0완료(2024년\xa0상반기).\n7.\xa0\n경쟁\n\xa0\n제품\nAltuviiio/BIVV001, efanesoctocog alfa (Sanofi) - hFVIII replacement therapy IV/QW, FDA approved\xa0시판\xa0중\xa0(2023년\xa02월), SB-525/PF-07055480 (Sangano Therapeutics, Pfizer) - recombinant AAV2/6 hFVIII gene therapy,\xa0임상\xa03상\xa0진행\xa0중\xa0(2020년), BMN270 (BioMarin Pharmaceutical) - AAV5-hFVIII,\xa0임상\xa03상\xa0진행\xa0중\xa0(2018년), Afstyla, NBP-601 (SK Chemical, CSL Behring) - hFVIII recombinant single chain IV/DIW, FDA approved\xa0시판\xa0중\xa0(2016년\xa05월).\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nUltrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice (Molecular Therapy Neucleic Acids, 2022)Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles (Molecular Therapy Neucleic Acids, 2020)\n9.\xa0\n시장\n\xa0\n규모\n2021년\xa0128억\xa0달러에서\xa0연평균\xa07.5%씩\xa0성장하여, 2031년에는\xa0269억\xa0달러에\xa0이를\xa0것이라고\xa0전망됨\xa0(제약산업분석기업; Allied Market Research).\n10.\n공동\n\xa0\n개발\n해당\xa0사항\xa0없음\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n\xa0\n(\n아\n)\xa0\n품목\n\xa0: GLS-8000\n1.\xa0\n구분\n핵산\xa0기반\xa0바이오신약\xa0- B형\xa0간염\xa0면역글로불린\xa0Plas-mAb\xa0\n2.\xa0\n적응증\nHBV\xa0감염\xa0예방\n3.\xa0\n작용\n\xa0\n기전\n간이식\xa0예정자\xa0또는\xa0모계\xa0감염\xa0우려자에\xa0B형간염\xa0면역글로불린\xa0Plas-mAb을\xa0투여하면,\xa0투여\xa0부위에서\xa0발현\xa0분비된\xa0치료\xa0물질이\xa0혈중에서\xa0HBV S\xa0항원을\xa0포함하고\xa0있는\xa0바이러스\xa0감염성\xa0입자를\xa0제거하고, HBV preS1을\xa0통한\xa0바이러스가\xa0숙주\xa0세포로의\xa0침입을\xa0방해함으로써\xa0HBV\xa0감염을\xa0예방.\n4.\xa0\n제품의\n\xa0\n특성\n기존\xa0B형간염\xa0바이러스\xa0면역글로불린이\xa0HBV S\xa0면역글로불린에\xa0한정되어\xa0있는\xa0것에\xa0반해\xa0S\xa0면역글로불린과\xa0preS1\xa0면역글로불린을\xa0동시에\xa0투여함으로써\xa0HBV\xa0감염을\xa0치료하고\xa0예방할\xa0수\xa0있음.HBV\xa0면역글로불린이나\xa0치료용\xa0백신을\xa0투여하는\xa0치료\xa0방법에\xa0비하여,\xa0핵산\xa0기반\xa0HBV\xa0면역글로불린\xa0Plas-mAb\xa0치료제는\xa0체외에서\xa0생산한\xa0단백질\xa0제재를\xa0체내에\xa0투여함으로써\xa0발생할\xa0수\xa0있는\xa0부작용을\xa0최소화할\xa0수\xa0있으며,체내에서\xa0지속해서\xa0mAb를\xa0생성할\xa0수\xa0있으므로\xa0일정\xa0기간\xa0동안\xa0지속적인\xa0약효를\xa0기대할\xa0수\xa0있음.면역\xa0글로불린\xa0치료제\xa0생산의\xa0어려움으로\xa0고가인\xa0기존\xa0HBV\xa0면역\xa0글로불린\xa0대비,\xa0핵산\xa0기반\xa0항체치료제의\xa0특성\xa0상,\xa0상대적으로\xa0낮은\xa0가격의\xa0면역글로불린을\xa0제공함으로써\xa0기존\xa0시장\xa0침투가\xa0쉽고\xa0신규\xa0시장\xa0확보가\xa0가능함.\n5.\xa0\n진행\n\xa0\n경과\n[신약후보물질\xa0연구]\n후보물질\xa0도출연구\xa0착수\xa0: 2017년\xa04월\xa03종의\xa0후보물질\xa0플라스미드\xa0제작\xa0및\xa0연구용\xa0시료\xa0생산\xa0완료/\xa0동물세포에서\xa0발현/항체\xa0생성과\xa0항원\xa0결합능력\xa0확인.\xa0실험동물에서\xa04종의\xa0후보물질로부터\xa0항체\xa0생성\xa0및\xa0체내\xa0분포\xa0경향\xa0분석\xa0연구\xa0진행\xa0중이고,\xa0항preS1\xa0면역글로불린과\xa0항S\xa0면역글로불린을\xa0동시에\xa0처리하면\xa0우수한\xa0B형\xa0간염\xa0바이러스\xa0억제\xa0효과를\xa0확인.코로나19\xa0연구개발에\xa0집중하기\xa0위해\xa0추가적인\xa0효능평가\xa0연구를\xa02022년\xa0하반기까지\xa0잠정\xa0연기.2023년\xa0상반기부터\xa0후보물질\xa0개선연구\xa0진행.\n6.\xa0\n향후\n\xa0\n계획\n높은\xa0국내\xa0분포를\xa0보이는\xa0B형\xa0간염\xa0바이러스\xa0유전자\xa0C형에\xa0대한\xa0억제\xa0효과를\xa0평가하는\xa0동물실험\xa0(2024년\xa0상반기).\xa0\n7.\xa0\n경쟁\n\xa0\n제품\n기존\xa0시장에서\xa0B형\xa0간염\xa0면역\xa0글로불린이\xa0허가되어\xa0사용되고\xa0있음\xa0(예\xa0: Cangene Corporation\xa0사\xa0HepaGamB,Grifols\xa0사\xa0HyperHEPB, Biotest Pharmaceuticals Corporation\xa0사\xa0Nabi-HB\xa0등), GC녹십자사의\xa0GC1102 (재조합\xa0HBV\xa0면역글로불린) : HBV\xa0관련\xa0간이식\xa0환자\xa0대상으로\xa0임상\xa02/3상\xa0시험\xa0진행\xa0중\xa0(2018년),\xa0차백신연구소의\xa0CVI-HBV-002 -신규\xa0항원(L-HBsAg)과\xa0면역증강제\xa0병용요법으로\xa0HBV\xa0치료용\xa0백신\xa0임상\xa02상\xa0진행\xa0중\xa0(2023년).\xa0현재\xa0개발되고\xa0있는\xa0 preS1\xa0면역글로불린\xa0제품은\xa0없음.\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nGeneration and Characterization of a Neutralizing Human Monoclonal Antibody to Hepatitis B Virus PreS1 from a Phage-Displayed Human Synthetic Fab Library (J. Microbiol. Biotechnol., 2018)Construction and Characterization of an Anti-Hepatitis B Virus preS1 Humanized Antibody that Binds to theEssential Receptor Binding Site (J. Microbiol. Biotechnol., 2017)\n9.\xa0\n시장\n\xa0\n규모\n세계\xa0B형\xa0간염\xa0치료제\xa0시장\xa0규모는\xa02022-2026년\xa04억\xa07,149만\xa0달러의\xa0증가가\xa0전망되나(Global Hepatitis B \xa0 \xa0 \xa0 \xa0 Therapeutics Market 2022-2026),핵산\xa0기반\xa0면역글로불린\xa0연구개발은\xa0초기\xa0개발단계이고\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\n공동\n\xa0\n개발\n해당\xa0사항\xa0없음\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n강원대학교\xa0산학협력단이\xa0보유한\xa0B형간염\xa0바이러스의\xa0preS1에\xa0특이하게\xa0결합하는\xa0항체\xa02종에\xa0대한\xa0특허와\xa0기술을\xa0양수함으로써\xa0독점적\xa0개발\xa0권리를\xa0확보함. (계약체결일\xa0: 2017년\xa04월\xa05일)\n1종\xa0후보물질\xa0국내\xa0특허\xa0등록\xa0완료\xa0(등록번호\xa0: KR 101864693 B1 /\xa0등록일자: 2018년\xa05월\xa030일)1종\xa0후보물질\xa0미국\xa0특허\xa0등록\xa0완료\xa0(등록번호\xa0: US 10196437 B2 /\xa0등록일자: 2019년\xa05월\xa02일)\n\xa0\n(\n자\n)\xa0\n품목\n\xa0: GLS-1200\xa0\n1.\xa0\n구분\n항염증\xa0치료\xa0신약-천연물\xa0유래\xa0성분,\xa0쓴맛\xa0수용체\xa0신호\xa0전달물질\n2.\xa0\n적응증\n만성\xa0축농증\xa0치료,\xa0코로나19\xa0감염\xa0방지\n3.\xa0\n작용\n\xa0\n기전\n키나(Cinchona)나무의\xa0나무껍질에서\xa0추출한\xa0성분인\xa0Quinine은\xa0호흡기관인\xa0부비동의\xa0쓴맛\xa0수용체를\xa0자극하여\xa0체내\xa0항염증\xa0물질의\xa0분비를\xa0유도함으로서,\xa0염증의\xa0원인인\xa0세균을\xa0제거하여\xa0만성\xa0축농증을\xa0치료.\xa0코로나19\xa0및\xa0독감을\xa0포함한\xa0다른\xa0바이러스에\xa0의한\xa0감염을\xa0예방.\n4.\xa0\n제품의\n\xa0\n특성\nQuinine은\xa0지난\xa0150년간\xa0말라리아\xa0치료제등의\xa0성분으로\xa0이용되었고\xa0우수한\xa0안전성이\xa0확인됨,\xa0비염\xa0및\xa0축농증\xa0치료\xa0시\xa0Quinine과\xa0반응성이\xa0있는\xa0쓴맛\xa0수용체를\xa0지닌\xa0환자를\xa0진단법에\xa0의해\xa0선별한다면\xa0치료\xa0효율을\xa0극대화할\xa0수\xa0있음.\nQuinine을\xa0코\xa0스프레이로\xa0투약하면\xa0코\xa0상피\xa0세포내에서\xa0산화질소(NO)\xa0가스를\xa0생성하여\xa0세포밖으로\xa0분비하게\xa0됨.\xa0코로나19\xa0바이러스가\xa0코를\xa0통해\xa0인체에\xa0진입하면\xa0상기도(upper respiratory tract)에\xa0존재하는\xa0코\xa0상피세포(nasal epithelial cell)에\xa0감염되어\xa0세포\xa0안으로\xa0바이러스\xa0유전자가\xa0삽입되고\xa0바이러스\xa0복제가\xa0일어남.\xa0이때,\xa0코로나19\xa0바이러스가\xa0감염된\xa0세포\xa0안으로\xa0Quinine\xa0투약으로\xa0생성된\xa0산화질소(NO)\xa0가스가\xa0이동하여\xa0바이러스의\xa0복제를\xa0저해함으로써\xa0감염을\xa0방지하게\xa0됨.\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01/2상]\xa0임상시험\xa0승인\xa0및\xa0시작일:\xa0미국\xa0FDA(2015.10),\xa0진행\xa0국가\xa0:\xa0미국,\xa0임상\xa0완료일\xa0: 2017년\xa05월\n[임상\xa02상]\xa0축농증\xa0치료\xa0임상시험\xa0승인,\xa0미국\xa0FDA(2020년\xa04월)\n[임상\xa02상]\xa0코로나19\xa0감염\xa0방지\xa0임상시험\xa0승인,\xa0미국\xa0FDA(2020년\xa04월),\xa0임상시험\xa0대상자의\xa050%\xa0이상의\xa0등록이\xa0완료(2020년\xa09월),\xa0미국\xa0내\xa0코로나19\xa0감염병\xa0유행의\xa0진원지이며\xa0다수의\xa0감염\xa0사례가\xa0발생하고\xa0있는\xa0루이지에나주\xa0바톤\xa0루지시에\xa02차\xa0임상시험\xa0실시기관을\xa0추가(2020년\xa09월).\xa0임상\xa0대상자를\xa0일반인으로\xa0확대해서\xa0진행할\xa0수\xa0있도록\xa0IRB\xa0승인을\xa0득함.(2021년\xa04월).\xa0대상자\xa0모집에\xa0대해\xa0지속적인\xa0노력으로\xa0184명\xa0등록(2022년\xa012월).\xa0하지만\xa0코로나\xa019\xa0감염\xa0대상자를\xa0모집하는데\xa0고충이\xa0큼.\n6.\xa0\n향후\n\xa0\n계획\n만성\xa0축농증\xa0치료제\xa0:\xa0코로나19\xa0감염병\xa0사태에\xa0따라\xa02상\xa0임상시험\xa0착수.\xa0축농증\xa0환자를\xa0대상으로\xa0하며,\xa0내시경\xa0부비강\xa0수술을\xa0받은\xa0환자에게\xa0GLS-1200\xa0혹은\xa0위약을\xa0치료받게\xa0한\xa0이후에\xa0질환에\xa0감염되는\xa0비율을\xa0평가하는\xa0것으로\xa0임상시험이\xa0설계되었으나, COVID-19\xa0관련\xa0임상시험으로\xa0인해\xa0중단함.코로나19\xa0감염방지\xa0코\xa0스프레이\xa0치료제\xa0:\xa0임상\xa02상\xa0연구\xa0종료\xa0(2022년) : 2023년에\xa0임상2상\xa0연구를\xa0종료하여,\xa0임상\xa0결과\xa0분석\xa0및\xa0임상시험\xa0결과보고서\xa0작성을\xa0수행할\xa0계획임.\n7.\xa0\n경쟁\n\xa0\n제품\n유사한\xa0작용기전의\xa0경쟁제품\xa0없음\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nBitter Tastes Bodyguards (2106, Scientific American),\nBacterial D-amino acids suppress sinonasal innate immunity through sweet taste receptors in \xa0solitary chemosensory cells (2017, Science Signaling)\n9.\xa0\n시장\n\xa0\n규모\n초기임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\xa0\n공동\n\xa0\n개발\n해당\xa0사항\xa0없음\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n미국\xa0University of Pennsylvania가\xa0보유한\xa0호흡기\xa0감염의\xa0치료제\xa0개발을\xa0위한\xa0쓴맛\xa0수용체\xa0신호\xa0 \xa0전달\xa0물질\xa0및\xa0쓴맛\xa0수용체\xa0진단법\xa0개발\xa0기술에\xa0대해\xa0당사가\xa0독점적인\xa0라이선스를\xa0갖게\xa0됨.(계약\xa0 \xa0체결일\xa0: 2018년\xa06월\xa020일)\xa0\n\xa0\n(\n차\n)\xa0\n품목\n\xa0: GLS-1027\xa0\n1.\xa0\n구분\n항염증\xa0치료\xa0신약-저분자량\xa0화학합성\xa0성분\n2.\xa0\n적응증\n당뇨병성\xa0신장\xa0질환\xa0등\xa0자가면역의\xa0치료,\xa0코로나19\xa0감염병\xa0중증\xa0방지\xa0치료.\n3.\xa0\n작용\n\xa0\n기전\n당뇨병성\xa0신장질환의\xa0원인인\xa0, Th 17\xa0세포를\xa0직접\xa0억제하여\xa0IL-17\xa0생성을\xa0감소시킴으로써\xa0치료함.\n4.\xa0\n제품의\n\xa0\n특성\nGLS-1027은\xa0염증\xa0질환의\xa0치료에\xa0이용되는\xa0경구용\xa0의약품으로, RA, 1형\xa0당뇨병, Colitis, Uveitis에서\xa0효능을\xa0확인하였고, 1상\xa0임상\xa0연구를\xa0통해\xa0약물의\xa0안전성을\xa0확인함.\n5.\xa0\n진행\n\xa0\n경과\n[임상\xa01상]\xa0임상시험\xa0승인\xa0및\xa0시작일:\xa0미국\xa0FDA(2008년\xa02월),\xa0진행\xa0국가\xa0:\xa0미국,\xa0임상\xa0완료일\xa0: 2008년\xa09월\xa0\n[임상\xa02상]-임상\xa0승인\xa0및\xa0시작일\xa0:\xa0미국\xa0FDA(2020년\xa011월),\xa0북마케도니아(2021년\xa07월\xa02일),\xa0국내\xa0식약처(2021년\xa09월\xa08일).국내\xa0임상시험\xa0개시\xa0방문\xa0완료(2022년\xa04월\xa08일)하고\xa0대상자\xa0모집\xa0및\xa0등록\xa0착수,\xa0코로나19\xa0감염된\xa0중등증\xa0입원환자\xa0수의\xa0급격한\xa0감소로\xa0인해\xa0환자\xa0모집의\xa0어려워\xa0국내\xa0임상시험\xa0조기\xa0종료(2022년\xa08월),\xa0미국과\xa0북마케도니아\xa0포함한\xa03개국에서\xa0132명\xa0대상자\xa0등록\xa0완료(2022년\xa06월\xa022일)\xa0및\xa0임상\xa0시험\xa0완료(2022년\xa012월),\xa0임상\xa02상 결과 분석 완료.\xa0국내 식약처에 종료보고서 제출 완료(2024년\xa04월\xa015일)\n6.\xa0\n향후\n\xa0\n계획\n코로나19\xa0감염\xa0후\xa0심각한\xa0폐질환\xa0방지\xa02상\xa0임상시험\xa0종료\xa0(2022년)\n7.\xa0\n경쟁\n\xa0\n제품\nMTX(methotrexate) :\xa0경구용\xa0anti-folate치료제,\xa0핵산\xa0대사효소\xa0억제,\xa0일시적\xa0염증\xa0억제, 35%\xa0치료율.\n8.\xa0\n관련\n\xa0\n논문\n\xa0\n등\nClin Immunol. 2007, JPET 2006, EJP 2008, BJ Pharmacol 2008\n9.\xa0\n시장\n\xa0\n규모\n초기\xa0임상\xa0단계이고,\xa0해당\xa0의약품\xa0시장이\xa0아직\xa0형성되지\xa0않아\xa0목표시장의\xa0예상\xa0규모를\xa0추정하기\xa0어려움.\n10.\xa0\n공동\n\xa0\n개발\n해당\xa0사항\xa0없음\n11.\xa0\n정부\n\xa0\n보조금\n해당\xa0사항\xa0없음\n12.\xa0\n기타\n\xa0\n사항\n해당\xa0사항\xa0없음\n②\xa0\n연구개발\n\xa0\n완료\n\xa0\n실적\n공시\xa0서류\xa0작성기준일\xa0현재\xa0개발이\xa0완료된\xa0신약은\xa0없습니다.\n③\xa0\n기타\n\xa0\n연구개발\n\xa0\n실적\n추가로\xa0기재하고자\xa0하는\xa0연구개발\xa0관련\xa0내용\xa0없습니다.\n']"
